Genetics of Digitocutaneous Dysplasia by Fukushima, Kaya
 





A thesis submitted for the degree of 
Bachelor of Medical Science with Honours 








Think and Wonder, 
Wonder and Think. 
 






The development of the human skeleton is a precisely controlled process. The study of 
Mendelian diseases involving abnormalities in the skeleton enables the idenfication of factors 
critical to skeletal development. 
Digitocutaneous dysplasia (DCD) is a rare genetic syndrome exhibiting abnormalities in the 
skeleton that are most pronounced in the hands and feet. This condition is caused by a single 
mis-splicing event that results in the in-frame deletion of 16 amino acids from the encoded 
filamin A protein (FLNA; NP_001104026.1:p.Val1724_Thr1739del). Tellingly, this region of 
FLNA has been shown to interact with the extracellular calcium-sensing receptor (CaSR). 
Activation of CaSR initiates downstream mitogen-activated protein kinase (MAPK) signaling 
that can trigger osteoblast recruitment and differentiation. 
This project aimed to explore the pathomechanisms that lead to the skeletal abnormalities in 
DCD. This was achieved using two approaches, one examining the effects of this FLNA variant 
on osteoblast function, and the other investigating the possible involvement of CaSR. 
Two immortalised cell lines, MC3T3-E1 and U2OS, were chosen to model osteoblasts. Given 
the murine origin of MC3T3-E1, the nucleotide sequence of mouse Flna was compared with 
that of human FLNA. It was discovered that rodents had what was equivalent to the pathogenic 
variant responsible for the mis-splicing of FLNA in humans. However, no mis-splicing was 
found in the mouse following the investigation of a publicly available mouse development 
RNA-seq dataset. Disrupting the splice site of interest in MC3T3-E1 using antisense 
oligonucleotides resulted in a mis-splicing event different to that associated with DCD. Taken 
together, these findings demonstrate that the regulation of splicing at this site differ between 
mice and humans. 
Antisense oligonucleotides were also transfected into human U2OS cells but no mis-splicing 
was induced. Subsequently, a transient transfection approach to introduce the misspliced form 
of FLNA via a plasmid vector was initiated. A satisfactory transfection efficiency was unable 
to be achieved and consequently, no clear results were obtained. 
Meanwhile, the expression of CASR was investigated using reverse transcription PCR. CASR 
was detected in mouse bone but not in two osteoblastic cell lines, MC3T3-E1 and U2OS. The 
apparent absence of CASR in these cell lines was thought to be due to this method lacking the 
sensitivity to detect very the low expression of this gene common in in vitro cultures. 
The experiments utilising antisense oligonucleotides along with the exploration of interspecific 
differences in the nucleotide sequence of FLNA has led to the uncovering of putative factors 
that influence mis-splicing at this site. The finding of Casr expression in bone has called 
attention to the possible role that osteocytes may have in the pathogenesis of DCD. Overall, 
this project has laid a foundation for further work and opened up some new avenues that can be 






First and foremost, I must say an enormous thank you to my supervisor Prof. Stephen Robertson. 
You welcomed me into your lab for a summer studentship and provided me with a stimulating 
experience that sparked in me a desire for more. I am so glad to have been able to undertake 
this BMedSc(Hons) project under your supervision. Your kind support and encouragements 
have been invaluable in helping me grow not only as a student researcher but as an individual. 
A huge thank you also goes to Dr Emma Wade, who supervised my wet lab work and helped 
shape my project. Prior to this year, I had very little experience in the lab but you managed to 
skilfully guide me through so many techniques. I cannot thank you enough for always being so 
approachable and willing to answer all my questions. You seem to have an endless supply of 
patience and advice and your positivity kept me excited for this project.  
To all members of the Robertson lab, both past and present, I would like to say thanks for being 
the wonderful bunch you are. A special thank you goes to Dr Zandra Jenkins for sharing her 
expertise and to Tim Morgan for teaching me the foundations of lab work during my summer 
studentship. Thank you to Liz Goodin, Ben Halliday, Amy Jones, and Annika Sjoeholm, for 
providing me with delightful chats and helpful advice in the lab. 
I would also like to thank the friendly people I have had the pleasure of sharing my office with. 
A special mention goes to Meghan Mulligan who made me feel so welcome when I first arrived, 
and Danielle Jenkins who provided some great chats when the office was eerily empty during 
the first level two lockdown. 
To all those people that I met in the pathology tearoom, thanks for the great company and the 
lively discussions during all those lunchtimes. I cannot mention you all but shoutout to Katrin 
Campbell, Amarni Thomas, Lorissa McDougall, Rosie Sullivan, Priyal Dass, and several others 
I have already mentioned, who I saw regularly. 
My thanks also go out to my friends outside the Hercus building for keeping in contact and 
providing me with a healthy distraction. And of course I owe my family a great many thanks 
for their love and support. 
Finally, I wish to express my grattitude towards the Maurice and Phyllis Paykel Trust and the 
Otago Medical School who have funded my year. Despite the unexpected challenges presented 
by COVID-19, this year has truly been incredible and certainly rich with learning which I will 
take with me into the next chapter of my life. 
  
Table of Contents 
 
v 
Table of Contents 
Abstract .............................................................................................................. iii 
Acknowledgements ............................................................................................ iv 
Table of Contents ................................................................................................ v 
List of Tables ...................................................................................................... ix 
List of Figures ..................................................................................................... x 
List of Abbreviations ......................................................................................... xi 
Chapter 1 Introduction ................................................................................ 2 
1.1 Overview .................................................................................................................... 2 
1.2 Digitocutaneous dysplasia (DCD)............................................................................ 3 
1.2.1 Clinical features of DCD .................................................................................... 3 
1.2.2 DCD is caused by a single recurrent variant in FLNA ....................................... 6 
1.2.3 An atypical case of DCD .................................................................................... 8 
1.3 Filamin A (FLNA) .................................................................................................... 9 
1.3.1 Diseases associated with FLNA .......................................................................... 9 
1.3.2 Functions of FLNA ........................................................................................... 11 
1.3.3 Structure of FLNA ............................................................................................ 11 
1.3.4 Mis-splicing of FLNA in DCD ......................................................................... 13 
1.4 Calcium-Sensing Receptor (CaSR) ....................................................................... 18 
1.4.1 Diseases associated with CASR ........................................................................ 18 
1.4.2 The role of CaSR in bone ................................................................................. 19 
1.4.3 Functional relationship between CaSR and FLNA .......................................... 21 
1.4.4 Possible role of CaSR-FLNA interaction in bone ............................................ 23 
1.5 Aims of study ........................................................................................................... 24 
Chapter 2 Materials and Methods ............................................................ 27 
2.1 Ethics........................................................................................................................ 27 
2.2 Cell culture .............................................................................................................. 27 
2.2.1 Cell lines and culture conditions ...................................................................... 27 
2.2.2 Cell counting and cell plating ........................................................................... 28 
Table of Contents 
 
vi 
2.3 RNA techniques ...................................................................................................... 28 
2.3.1 RNA isolation ................................................................................................... 28 
2.3.2 DNase treatment of RNA isolate ...................................................................... 29 
2.3.3 Synthesis of cDNA from total RNA ................................................................. 29 
2.4 Quantitative PCR (qPCR) ..................................................................................... 29 
2.4.1 qPCR reaction set up ........................................................................................ 29 
2.4.2 Analysis of qPCR data ...................................................................................... 30 
2.5 Statistical analysis of quantitative data ................................................................ 31 
2.6 Phylogenetic analysis of FLNA sequence.............................................................. 32 
2.7 Alizarin Red S staining for calcium deposits ....................................................... 32 
2.7.1 Fixing of cells ................................................................................................... 32 
2.7.2 Alizarin Red S staining ..................................................................................... 33 
2.8 Antisense oligonucleotide (AON) transfections ................................................... 33 
2.8.1 AON design ...................................................................................................... 33 
2.8.2 AON transfection .............................................................................................. 34 
2.9 Polymerase chain reaction (PCR) ......................................................................... 35 
2.9.1 RT-PCR primer design ..................................................................................... 35 
2.9.2 PCR reaction ..................................................................................................... 35 
2.9.3 Gel electrophoresis ........................................................................................... 36 
2.10 Sanger sequencing .................................................................................................. 37 
2.10.1 Pre-sequencing reaction for clean-up of PCR products.................................... 37 
2.10.2 Sequencing reaction (BigDye Terminator)....................................................... 37 
2.10.3 Clean-up of sequencing reaction ...................................................................... 38 
2.10.4 Sequencing service ........................................................................................... 38 
2.10.5 Sequence analysis ............................................................................................. 39 
2.11 Cloning techniques ................................................................................................. 39 
2.11.1 Ligation, transformation, and culture with the pGEM-T vector ....................... 39 
2.11.2 Lysogeny broth culture ..................................................................................... 39 
2.11.3 Plasmid DNA purification ................................................................................ 40 
2.12 Construction of the shRNA-eGFP expression plasmid ....................................... 41 
2.12.1 Digestion of the vector ..................................................................................... 42 
2.12.2 Design and production of shRNA fragments ................................................... 42 
2.12.3 Q5 PCR amplification of hU6 and eGFP fragments ........................................ 43 
2.12.4 HiFi assembly of plasmids ............................................................................... 45 
2.12.5 Colony PCR ...................................................................................................... 45 
Table of Contents 
 
vii 
2.12.6 Plasmid transfections ........................................................................................ 46 
2.13 CaSR stimulation and measurement of MAPK activation ................................. 47 
2.13.1 Calcium and strontium treatment of T24 cells ................................................. 47 
2.13.2 Western blotting analysis.................................................................................. 48 
Chapter 3 Results ........................................................................................ 51 
3.1 Investigating the effects of DCD-FLNA on osteoblast function ......................... 51 
3.1.1 Introduction ...................................................................................................... 51 
3.1.2 MC3T3-E1 differentiation can be examined using Sp7 and Runx2 ................. 52 
3.1.3 Mus musculus has the DCD variant in Flna but exhibits normal splicing ....... 54 
3.1.4 Other species in the order Rodentia also have the DCD variant ...................... 57 
3.1.5 Human U2OS cell line can be stimulated to form a mineralised matrix .......... 61 
3.1.6 AONs could not reproduce the mis-splicing event responsible for DCD ........ 63 
3.1.7 Construction of a DCD-FLNA plasmid for transfecting into MC3T3-E1 ....... 67 
3.2 Investigating the possible role of CaSR in DCD .................................................. 72 
3.2.1 Introduction ...................................................................................................... 72 
3.2.2 Expression of CaSR in MC3T3-E1 at the mRNA level ................................... 73 
3.2.3 Expression of CaSR in human cell lines at the mRNA level ........................... 74 
3.2.4 Stimulation of T24 cells with calcium and strontium....................................... 77 
3.3 Summary of findings .............................................................................................. 79 
Chapter 4 Discussion .................................................................................. 82 
4.1 Overview .................................................................................................................. 82 
4.2 Developing an in vitro model of DCD.................................................................... 82 
4.2.1 Modelling of diseases of bone .......................................................................... 82 
4.2.2 Mis-splicing of FLNA in DCD ......................................................................... 85 
4.2.3 Regulation of Flna splicing in mice and other rodents .................................... 86 
4.3 CaSR in the pathogenesis of DCD ......................................................................... 89 
4.3.1 Expression of CaSR at the mRNA level ........................................................... 89 
4.3.2 CaSR-mediated MAPK activation in T24 cells ................................................ 91 
4.3.3 Reconsideration of the role of CaSR in DCD................................................... 92 
4.4 Clinical applications of findings ............................................................................ 93 
4.5 Future perspectives................................................................................................. 95 
4.6 Conclusions.............................................................................................................. 96 
References .......................................................................................................... 99 
Table of Contents 
 
viii 
Appendices ...................................................................................................... 112 
Appendix A: Primers for qPCR ...................................................................................... 113 
Appendix B: Transcript IDs ............................................................................................ 114 
Appendix C: RT-PCR primers ........................................................................................ 115 
Appendix D: Primers for plasmid construction............................................................. 116 
Appendix E: Western blot solutions ............................................................................... 118 
 
  
List of Tables 
 
ix 
List of Tables 
Table 1-1: FLNA Ig 14-17 interaction partners........................................................................ 16 
 
Table 2-1: Cycling conditions for qPCR .................................................................................. 30 
Table 2-2: AON sequences ....................................................................................................... 34 
Table 2-3: Standard thermal cycling conditions for PCR......................................................... 36 
Table 2-4: Touchdown program thermal cycling conditions for PCR ..................................... 36 
Table 2-5: BigDye Terminator thermal cycling conditions ...................................................... 38 
Table 2-6: Sequences of shRNA1, shRNA2, and shRNAscr ................................................... 42 
Table 2-7: Touchdown thermal cycling conditions for Q5 PCR .............................................. 44 
Table 2-8: Amounts of vector and insert added to a 5 μL assembly reaction .......................... 45 
 
  
List of Figures 
 
x 
List of Figures 
Figure 1.1: Clinical features of DCD.......................................................................................... 3 
Figure 1.2: The recurrent DCD variant lies in the exonic section of the 5’ splice region .......... 8 
Figure 1.3: Variant responsible for the atypical case of DCD. ................................................... 9 
Figure 1.4: Structure of the FLNA homodimer bound to F-actin. ........................................... 12 
Figure 1.5: Location of variants in FLNA causative of OPDSD. ............................................. 14 
Figure 1.6: Proposed CaSR-FLNA-TAK1/TAB2-p38 pathway. ............................................. 24 
 
Figure 2.1: Construction of the shRNA-eGFP dual expression plasmid. ................................. 41 
 
Figure 3.1: Expression levels of osteoblast markers in MC3T3-E1 ......................................... 54 
Figure 3.2: Alignment of the human FLNA and mouse Flna sequences .................................. 55 
Figure 3.3: Alternative splicing events involving mouse Flna exon 30 ................................... 57 
Figure 3.4: Phylogenetic tree of 100 vertebrate species. .......................................................... 59 
Figure 3.5: Alignment of human FLNA with that from nine species of rodent. ....................... 60 
Figure 3.6: Alizarin Red S staining for calcium deposits produced by U2OS ......................... 62 
Figure 3.7: Positions of AON1 and AON2 relative to the exon-intron junction ...................... 64 
Figure 3.8: AON transfections into MC3T3-E1 ....................................................................... 65 
Figure 3.9: AON transfections into U2OS ............................................................................... 66 
Figure 3.10: AON transfections into primary control fibroblasts ............................................ 67 
Figure 3.11: Design of the dual expression plasmid ................................................................ 68 
Figure 3.12: Knockdown of Flna in MC3T3-E1 ...................................................................... 69 
Figure 3.13: Transfection efficiency in MC3T3-E1 and HEK293FT ...................................... 71 
Figure 3.14: Casr expression was not able to be detected in MC3T3-E1 ................................ 74 
Figure 3.15: mRNA expression of CASR was detected in T24 ................................................ 75 
Figure 3.16: Repeats of RT-PCR for CASR on T24 ................................................................. 76 
Figure 3.17: Effects of CaCl2 and SrCl2 treatment of T24 ....................................................... 78 
Figure 3.18: Effects of CaCl2 and SrCl2 treatment of serum deprived T24 ............................. 79 
  
List of Abbreviations 
 
xi 
List of Abbreviations 
ACS  American Chemical Society 
ADH1  Autosomal dominant hypocalcaemia type 1 
ALP  Alkaline phosphatase 
AON  Antisense oligonucleotide 
CaSR  Calcium-sensing receptor 
cDNA  Complementary deoxyribonucleic acid 
CES  Combined enhancer solution 
CKCO Condition characterised by contractures, keloid, cardiac and optic anomalies 
CST  Cell Signaling Technology 
ddNTP Dideoxynucleotide triphosphate 
DCD  Digitocutaneous dysplasia 
DCD-FLNA Variant of filamin A missing 16 amino acids, observed in DCD 
DMEM Dulbecco’s modified eagle medium 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
eGFP  Enhanced green fluorescent protein 
ELISA Enzyme-linked immunosorbent assay 
ERK  Extracellular signal-regulated kinase 
FBSF  Fetal bovine serum, filtered 
FHH1  Familial hypocalciuric hypercalcemia type 1 
FLNA  Filamin A 
FLNB  Filamin B 
FLNC  Filamin C 
FMD1  Frontometaphyseal dysplasia type 1 
GPCR  G protein-coupled receptor 
HCl  Hydrochloric acid 
IDF  Infantile digital fibromatosis 
iPSC  Induced pluripotent stem cell 
MAPK Mitogen-activated protein kinase 
MEM  Minimum essential medium 
MNS  Melnick-Needles syndrome 
List of Abbreviations 
 
xii 
mRNA Messenger ribonucleic acid 
MSC  Mesenchymal stem cell 
NEB  New England Biolabs 
NSHPT Neonatal severe hyperparathyroidism 
nt  Nucleotides 
OPD1  Otopalatodigital syndrome type 1 
OPD2  Otopalatodigital syndrome type 2 
OPDSD Otopalatodigital spectrum disorders 
PCR  Polymerase chain reaction 
PBS  Phosphate buffered saline 
PFA  Paraformaldehyde 
PTH  Parathyroid hormone 
p-ERK Phosphorylated ERK1/2 
p-p38  Phosphorylated p38 
qPCR  Quantitative polymerase chain reaction 
RNA  Ribonucleic acid 
RNase  Ribonuclease 
RT-PCR Reverse transcription polymerase chain reaction 
RTP  RNA-to-protein 
SDS  Sodium dodecyl sulfate 
shRNA Short hairpin ribonucleic acid 
SRE  Serum response element 
TEMED N,N,N’,N’-Tetramethylethylenedimine 
TOD  Terminal osseous dysplasia 
TODPD Terminal osseous dysplasia with pigmentary defects 
 
Symbols for genes are italicised while the corresponding protein products are not (e.g. FLNA 
gene vs FLNA protein). Full capital letters are used when referring to human genes (e.g. FLNA) 











Chapter 1 Introduction 
1.1 Overview 
The human skeleton is a dynamic organ that is constantly being remodelled in response to cues 
from the external and internal environment. This occurs through the combination of bone 
resorption and bone deposition. Disorders of bone result when there is a dysregulation of one 
or both of these processes (1). By far, the most common disease of bone is age-related 
osteoporosis – this presents a significant health burden which is set to increase with the ageing 
population (2). 
Studies on rare diseases of bone have provided mechanistic insights into the processes that 
underpin skeletal modelling and remodelling. The development of next generation sequencing 
technology has allowed the advancement of knowledge surrounding the genetic aetiology of 
these rare diseases, and functional studies on these genetic variants have elucidated key 
signaling pathways active in bone. Improved understanding of bone biology allows the 
identification of possible targets for therapeutic interventions aiming to treat both rare and 
common diseases of bone. 
The work in this thesis focuses on a rare genetic disease affecting skeletal development, known 
as digitocutaneous dysplasia (DCD). While the genetic defect responsible has already been 
identified, the mechanisms by which this genetic variant gives rise to abnormal bone 
development remains elusive (3). In order to explore such mechanisms, in vitro cell cultures 
were used to study the functional consequences of this genetic defect in osteoblastic (bone 





1.2 Digitocutaneous dysplasia (DCD) 
1.2.1 Clinical features of DCD 
Digitocutaneous dysplasia (DCD) is a genetic syndrome that exhibits abnormal skeletal 
development (4). It is extremely rare, and there have only been thirty-five previously reported 
cases from twenty-one unrelated families (3,4,13–22,5,23,6–12). It is an X-linked disorder with 
presumed prenatal male lethality, inferred from the absence of affected males and the reduced 
male:female offspring ratio in affected females (3,9). 
Formerly known as terminal osseous dysplasia with pigmentary defects (TODPD) or more 
simply terminal osseous dysplasia (TOD), this syndrome was first recognised by Bacino et al 
(8) to be defined by the presence of three major features: skeletal abnormalities, digital 
fibromatosis, and skin defects (Figure 1.1). 
   
   
Figure 1.1: Clinical features of DCD. Triad of skeletal dysplasia, digital fibromatosis, and skin defects typical of 
DCD. (A) Hand radiograph showing a malformed metacarpal (red arrow). (B) Digital fibromata on the lateral 
aspects of the tips of the third and fourth digits (blue arrows). (C) Hyperpigmented atrophic lesion in the temporal 
region lateral to the eyebrow (yellow arrow) along with depressed hyperpigmented spots on the cheek (yellow 
arrowheads). 
 
Images modified and reproduced with permission from Azakli et al. (23) 
 
As the original name suggests, the ‘osseous dysplasia’ or the skeletal abnormalities are most 
pronounced in the ‘terminal’ or distal limbs, i.e. the hands and the feet. Clinically, this is 
observed as a variable combination of clinodactyly (curvature of the digits in the plane of the 




palm), brachydactyly (shortening of the digits), and camptodactyly (fixed flexion deformity in 
the digits, usually referring to the proximal interphalangeal joint) (22,23). Although these 
descriptors apply to both the hands and the feet, these features are more difficult to discriminate 
in the feet and therefore reports are often limited to ‘overlapping toes’ (13,19,23). 
Radiologically, unusually short or underdeveloped metacarpals and metatarsals are detected 
and are often accompanied by hypoplasia of one or more phalanges (Figure 1.1A) (3,23). A 
detailed skeletal survey conducted by Brunetti-Pierri et al. (17) was able to confirm the 
persistence of these features into adulthood. Fusion of bones (carpal and tarsal coalitions, 
carpal-metacarpal or tarsal-metatarsal fusions), were also identified in this study (17). This 
feature was previously infrequently described in this syndrome (15) perhaps due to most 
radiological investigations having been done prior to the bones being fully ossified. 
Additionally, it was discovered that the skeletal abnormalities were more widespread than 
initially thought, with the presence of abnormal bony architecture (e.g. striations, amorphous 
ossification, lucent defects with sclerotic borders) being detected in proximal limb bones such 
as the humerus and the femur (17). The generalised skeletal involvement could be indicative of 
a more fundamental defect in the regulation of bone development. 
The second key feature of DCD, the digital fibromata, are round nodules or tumours that 
develop on the fingers and toes. They typically appear in the first few months of life as firm, 
non-tender swellings on the lateral aspects of the distal ends of the fingers and toes (Figure 
1.1B) (10,13,14,23). While they initially undergo a phase of rapid growth, spontaneous 
regression ensues soon after – usually sometime during childhood (10). Consequently, digital 
fibromata are absent in affected adults, although sometimes scar-like lesions on the fingertips 
remain, marking the areas where they used to be located (8,10). The clinical progression of the 
digital fibromata is remarkably similar to another condition known as infantile digital 




and is histologically distinguished from the digital fibromata in DCD by the presence of 
intracytoplasmic inclusion bodies (12,24). The inclusion bodies were initially demonstrated to 
be absent in all digital fibromata sampled from individuals with a diagnosis of DCD 
(3,5,7,10,12,13,18). However, a single case of DCD was recently reported where inclusion 
bodies were detected in the digital fibromata (22). This might suggest that the underlying 
pathology is shared between these disorders. Although, unlike DCD, cases of IDF have been 
sporadic and no known causes have been identified – genetic or acquired (24,25). 
The third key feature of DCD is the skin defects. They are depressed or atrophic, apparently 
hyperpigmented patches, that are usually observed on the temporal regions of the face lateral 
to the eyebrows (Figure 1.1C). Note that the histological evidence for increased pigmentation 
in these lesions has been inconsistent (10,20), and consequently dermatologists have preferred 
the term DCD over TODPD for this syndrome (22).  
While skeletal abnormalities, digital fibromata, and skin defects are the most striking features 
of this syndrome, other features have also been reported, albeit variably. These include 
accessory gingival frenula (8,10,11,13), iris coloboma (8,10,23), dysplastic teeth (3,11,19,20), 
and cardiac septal defects (8,10,16,20,23). 
It has been proposed that a possible contributor to the phenotypic variability is the X-linked 
nature of this syndrome (9). In females, random X-inactivation (a phenomena whereby dosage 
compensation of the X chromosome is attained) results in two populations of cells: one with 
most genes on the maternal X-chromosome silenced and the other with most genes on the 
paternal X-chromosome silenced (26). Individuals with DCD (which are all female) will exhibit 
the effects of the disease only in cells where the affected allele is transcriptionally active. 
Interestingly, individuals with DCD have been found to show highly skewed X-inactivation 




chromosome carrying the affected allele (9). However, the level of skewing in blood did not 
correlate with severity of the clinical phenotype, probably because this did not reflect the 
inactivation patterns in other tissues. 
1.2.2 DCD is caused by a single recurrent variant in FLNA 
The variant responsible for causing DCD is a single synonymous transition that affects the last 
nucleotide of exon 31 in the FLNA gene (NM_001110556.1:c.5217G>A) (16). To date, all cases 
of DCD, for which genetic analysis has been conducted, have been shown to carry this 
pathogenic variant in FLNA (3,16,18–21,23). Note that FLNA resides on the X chromosome 
and all affected individuals have been female heterozygotes. Homozygosity or hemizygosity 
for this variant (in females and males respectively) is presumably non-survivable as such 
occurrences have never been reported. 
This variant was predicted to be synonymous at the protein level. However, its location at the 
exon-intron boundary meant that it had the potential to alter the encoded protein through the 
disruption of splicing (16). Splicing is an essential part of pre-mRNA processing and it involves 
the removal of introns and joining of adjacent exons to produce mature mRNA that can be used 
for translation. The 5’ splice region consists of the six nucleotides at the 5’ end of the intron 
and the three nucleotides at the 3’ end of the preceding exon (Figure 1.2A) (27). The appropriate 
sequence at the 5’ splice region is necessary for the proper recognition of the exon-intron 
boundary (28), and consequently variants that alter this sequence can cause abnormal splicing 
and result in disease (27). 
However, only the first two nucleotides at the 5’ end of the intron, which make up the splice 
donor, are strictly conserved (with exceptions, see ref. (29)). The other nucleotides show 




(28). Contributing to the complexity of this issue is the influence of other factors such as 
splicing enhancers and silencers which are degenerate and consequently difficult to define (28). 
The only way to prove that a certain variant in the 5’ splice region is pathogenic, is to 
demonstrate the presence of an aberrantly spliced transcript. 
Demonstration of the mis-splicing of FLNA in DCD proved difficult because the affected allele 
was not transcriptionally active in sampled skin fibroblasts from these individuals (a 
consequence of the extremely skewed X-inactivation patterns) (16). However, the expression 
of the disease allele was detected in three fibroma samples obtained from a single individual, 
and it was found that this G>A variant promoted the use of a cryptic splice site positioned 5’ to 
the original site (16). The result of this was the removal of the last forty-eight nucleotides of 
exon 31 during splicing of the FLNA pre-mRNA molecule (Figure 1.2B) (16). At the protein 
level, this is an in-frame deletion of sixteen amino acid  residues near the middle of the encoded 
filamin A protein (FLNA; NP_001104026.1:p.Val1724_Thr1739del) (16). It is thought that 
this alters the protein structure in a way that disrupts specific functions of FLNA; however, the 












Figure 1.2: The recurrent DCD variant lies in the exonic section of the 5’ splice region of FLNA exon 31. (A) The 
5’ splice region encompasses the last three nucleotides of the exon and the first six nucleotides of the following 
intron. The splice donor dinucleotide is the most conserved position in this region; guanine and uracil take these 
positions in ~99% of all 5’ splice sites. (B) Normal splicing of FLNA involves the removal of an intron to join 
exon 31 and 32. The G>A transition at the last nucleotide of exon 31 results in the use of a cryptic splice site 
positioned 5’ to the original splice site resulting in the removal of the forty-eight nucleotides at the end of exon 31 
during splicing. 
 
Figure created using Microsoft PowerPoint for Mac. 
 
1.2.3 An atypical case of DCD 
A case brought to our attention through personal communication (not yet published in the 
literature) deserves a mention here as it is highly relevant to the work that follows. A 6-month-
old female was given a clinical diagnosis of DCD on the basis of multiple digital fibromata, 
multiple oral frenulae, and skeletal abnormalities of the hands including metacarpal hypoplasia. 
In addition to these features, she also developed restrictive cardiomyopathy, interstitial lung 
disease (with atelectasis and bronchiectasis), and tonic seizures, none of which have been 
previously associated with DCD. This individual subsequently died from heart failure at the 
age of 5.  
Analysis of FLNA in this individual did not demonstrate the presence of the recurrent variant 
(NM_001110556.1:c.5217G>A) found in previously reported cases of DCD; however, a novel 




to the recurrent variant (see Figure 1.3). The mis-splicing event identical to that previously 
demonstrated by Sun et al. (16) (leading to the deletion of 16 amino acids in FLNA) was 
detected in the cardiac tissue of this individual postmortem (but not in lung or skin, presumably 
due to skewed X-inactivation), thus confirming the pathogenicity of this novel variant. 
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Figure 1.3: Variant responsible for the atypical case of DCD. Position of the NM_001110556.1:c.5217+5G>C 
variant found in the atypical case of DCD in relation to the recurrent c.5217G>A variant. Part of the sequence 
from the end of exon 31 (in capitals) to the start of intron 31 (in lowercase) of FLNA is shown. The dashed line 
separates the exon from the intron. The variants are indicated in red font. The reference sequence was obtained 
from Ensembl version 101 (31), transcript ID: ENST00000369850.10. 
 
Figure created using Microsoft Word for Mac. 
 
It is possible that this c.5217+5G>C variant also produces other mis-spliced transcripts to 
produce the phenotypic features not typical for DCD in this individual. However, this was not 
specifically investigated, and the method used to demonstrate mis-splicing (RT-PCR) had 
limited ability to detect other transcripts, and therefore this remains unclear.  
1.3 Filamin A (FLNA) 
1.3.1 Diseases associated with FLNA 
Gain-of-function variants in FLNA have been associated with the otopalatodigital spectrum dis-
orders (OPDSD), of which DCD is one (30). These disorders are characterised by a combination 
of skeletal anomalies and other congenital defects. There are five other disorders in this group: 




type 1 (FMD1), Melnick-Needles syndrome (MNS), and a more recently described syndrome 
of joint contractures, susceptibility to keloid formation, and cardiac valvular and optic tract 
defects (CKCO) (30). As with DCD, these disorders are each caused by restricted sets of 
variants in FLNA that cluster in one or several regions along this gene (30). The clustering of 
variants is suggestive of a pathogenesis that involves the dysregulation of specific functions 
residing in different regions of the encoded FLNA protein to produce these distinct, yet 
overlapping phenotypes. 
Other conditions that have been associated with pathogenic variants in FLNA include: 
periventricular nodular heterotopia (a neuronal migration disorder) (32), X-linked congenital 
intestinal pseudo-obstruction (an intestinal motility disorder) (33), familial cardiac 
myxomatous polyvalvular dystrophy (34), and macrothrombocytopenia (35). These conditions 
can co-exist in the same individual, and it is thought that they are caused by variants which fall 
under the loss-of-function category  (30). These may either involve localised loss-of-functions 
(e.g. affecting a single functional domain while leaving the rest of the FLNA protein intact) or 
through a global reduction of function (e.g. decreased abundance of the protein). 
The atypical case of DCD introduced in the previous section could be a mixed phenotype 
(36,37), with the typical features of DCD representing a gain-of-function effect, while the 
interstitial lung disease (38) and the tonic seizures (possible periventricular nodular heterotopia) 
representing a loss-of-function effect. As suggested earlier, the novel c.5217+5G>C variant 
may be inducing other mis-splicing events that produce transcripts responsible for the loss-of-
function effects. For example, out-of-frame transcripts that are degraded through nonsense-




1.3.2 Functions of FLNA 
FLNA is a widely distributed cytoskeletal protein with diverse and complex functions in various 
organ systems around the body. At the cellular level, FLNA is important for cell spreading and 
migration (39) and the protection of cells from mechanical stress (40,41). Both of these 
functions are mediated by the binding of FLNA to F-actin, which allows the cross-linking and 
reorganisation of the actin cytoskeleton. 
FLNA also is important for the localisation of other proteins within the cell (e.g. retention of 
transcription factors in the cytoplasm) (42), and the organisation of proteins into groups that 
function in a common signaling pathway (i.e. FLNA serves as a signalling scaffold) (43). These 
functions are mediated by the ability of FLNA to bind a wide variety of transmembrane and 
cytoplasmic proteins. 
Although the term ‘scaffold’ might suggest an inert, stationary structure, FLNA is quite the 
opposite. FLNA structure can be altered by mechanical forces (44), phosphorylation (45), 
partner binding (46), and proteolysis (47). All of these factors contribute to the regulation of 
the abovementioned functions of FLNA. 
1.3.3 Structure of FLNA 
FLNA is a large, 280 kDa protein composed of an N-terminal actin-binding domain, followed 
by twenty-four repeating structures that are immunoglobulin-like (Ig 1-24) (48). These repeats 
are organised into rod domain-1 (Ig 1-15), rod domain-2 (Ig 16-23), and the C-terminal self-
association domain (Ig 24) (48). Rod domain-1 and rod domain-2 are separated by a region 
named hinge 1, while rod domain-2 and the self-association domain are separated by hinge 2 
(49,50). FLNA exists as a homodimer and forms a V-shaped structure that allows the cross-





Figure 1.4: Structure of the FLNA homodimer bound to F-actin. The red arrows indicate the location of the sixteen 
amino acid deletion responsible for DCD. The N-terminal actin binding domain is depicted in yellow. The 
immunoglobulin-like repeats are shown as blue cylinders (Ig 1, Ig 8, Ig 15, and Ig 23 are numbered for orientation). 
Rod domain-1 and rod domain-2 are labelled, showing that they are made up of Ig 1-15 and Ig 16-23 respectively. 
Ig 24, in green, serves as the dimerization domain. Hinge 1 (H1) and hinge 2 (H2) are also labelled here. 
 
Figure modified and reproduced with permission from Zhou et al. (51) 
 
In broad terms, the region of FLNA preceding hinge 1 (i.e. actin-binding domain and rod 
domain-1) functions in actin-binding (52), while the region after hinge 1 (i.e. rod domain-2 and  
the self-association domain) is important for the scaffolding function. Pertinently, the vast 
majority of interactions with binding partners occur in rod domain-2 of FLNA, thus bringing 
components of signalling cascades into close proximity (50). Meanwhile, the two hinge regions 
provide flexibility, with hinge 1 in particular being important for maintaining the viscoelastic 
properties of the FLNA–F-actin network (53). Both hinge 1 and hinge 2 possess a calpain 
cleavage site (48). Such cleavage results in the release of rod domain-2 which is then 




1.3.4 Mis-splicing of FLNA in DCD 
As previously described in section 1.2.2, a single mis-splicing event in FLNA has been 
associated with DCD (16). This event results in the exclusion of sixteen amino acid residues 
from the full length protein. This in-frame deletion in Ig 15, just before hinge 1, is expected to 
alter the secondary structure and thus disrupt normal function of FLNA to result in the disease 
phenotype, although the exact mechanisms are yet unknown (3,30). 
Insights from allelic conditions described in section 1.3.1 may provide clues about the 
pathogenesis of this disease. Firstly, the clinical similarities between DCD and other OPDSD 
suggest that DCD is caused by gain-of-function in FLNA rather than a loss-of-function (30). 
Secondly, the clustering of variants responsible for OPDSD in Ig 15 could mean that the DCD 
variant is affecting a region of FLNA that has an important function in normal skeletal 
development (Figure 1.5A). Note that the skeletal abnormalities do differ between the different 
conditions (e.g. prominent supraorbital ridges and skull base sclerosis are observed in FMD1 
(54) but not in DCD) suggesting that the variants responsible for these conditions affect the 
same function of FLNA but in a different manner, to produce these distinct phenotypes. 
To show the spatial relationship between the FMD variants and the DCD deletion, these have 
been mapped onto filamin B (FLNB) Ig 15 solution structure (PDB ID: 2DMB) (55) which is 
homologous to FLNA Ig 15, as no structure has yet been described for the latter (Figure 1.5B). 
One FMD variant is located within the region of the DCD deletion (NP_001447:p.Gly1728Cys) 
(56), while another lies adjacent to the beginning of the deletion (p.Cys1723Trp; Dr Emma 
Wade, Department of Women’s and Children’s Health, University of Otago, personal 
communication). A further two variants, also unpublished, have been found within Ig 15, and 












Figure 1.5: Location of variants in FLNA causative of OPDSD. (A) Variants responsible for the otopalatodigital 
spectrum of disorders (OPDSD) are mapped onto a diagrammatic representation of the FLNA protein. ‘Hotspots’ 
harbouring multiple variants causative of these disorders are denoted with larger symbols. Note the clustering of 
variants around Ig 15. (B) Structure of FLNB Ig 15 which is homologous to that of FLNA Ig 15. The sixteen amino 
acid deletion responsible for DCD is shown in grey, while the FMD1 variants found in this repeat are shown in 
red. ABD, actin binding domain; CKCO, syndrome consisting of contractures, keloid, cardiac defects and optic 
anomalies; DCD, digitocutaneous dysplasia; FMD, frontometaphyseal dysplasia; H1, hinge 1; H2, hinge 2; MNS, 
Melnick-Needles syndrome; OPD, otopalatodigital syndrome. 
 
Figures reproduced modified with permission from Wade et al. (30) and Tomizawa et al. (55) 
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Interestingly, there is a variant nearby in Ig 14 that is responsible for CKCO. This condition 
shares many features with other disorders on the OPD spectrum including joint contractures 
and cardiac/valvular abnormalities (i.e. some pathogenesis is shared) but no defects in 
ossification are observed – suggesting that the gain-of-function effect is not active in bone tissue 
(30,57,58). This observation emphasises the fact that gain-of-function variants in FLNA have 
quite specific effects on the function of the encoded protein. 
Clearly, the section of FLNA that is removed due to mis-splicing of FLNA in DCD is integral 
to its function since hemizygosity in males is presumed embryonic lethal (3,9). Curiously, a 
large deletion between Ig 14 and Ig 17 of FLNA (thus encompassing the sixteen amino acid 
deletion in Ig 15 observed in DCD), has been found to be responsible for a severe but male-
survivable form of FMD (Dr Emma Wade, Department of Women’s and Children’s Health, 
University of Otago, personal communication). Evidently, the smaller deletion confers a more 
profound gain-of-function. This is perhaps through the dysregulation of the functions of FLNA 
that reside in Ig 14-17, which remain intact in DCD but are removed in the abovementioned 
case of FMD. 
Such an effect could be mediated by alterations in the local secondary structure of FLNA that 
leads to the dysregulation of the interactions with its binding partners. To date, twenty-one 






Table 1-1: FLNA Ig 14-17 binding partners 
Gene Protein Ig repeat on FLNA  References 
MRTFA MKL1 4-7, 16-21 (59) 
FOXC1 FOXC1 4-9, 16-21 (60) 
RACK1 RACK1 8-15 (61) 
CFTR CFTR 9, 12, 17, 19, 21, 23 (62,63) 
PRNP Pro-Prion protein 10, 16-18, 20, 21, 23 (64,65) 
FURIN Furin 13-14 (66) 
CASR CaSR 14-15 (67–69) 
KCNMB1 BKCa β1 subunit 14-19 (70) 
NPHP1 Nephrocystin 15-16 (71) 
PACSIN2 Syndapin II 15-16, 20 (72,73) 
ECSCR ECSM2 15-16, 19-21 (74) 
FILIP1 FILIP1 15-18 (75) 
TRAF2 TRAF2 15-19 (76) 
CAPN1/2 Calpain-1 and -2 Cleavage at hinge 1 (48,77) 
CMIP Tc-mip 16-18 (78) 
GRB7 Grb7 16-19 (79) 
DNM1L Drp1 16-23 (80) 
RRN3 TIF-90 16-24 (81) 
GP1BA GPIba 17 (82) 
SH2B1 Adaptor protein SH2B1 beta 17-23 (83) 
 
Although specific Ig repeats of FLNA to which they interact are indicated, these are not 
necessarily precise or accurate. For instance, the mapping of the binding site of syndapin II on 
FLNA in two different studies have given conflicting results. The earlier study identified Ig 15-
16 to be the minimum region necessary for binding using a series of truncations (72), while a 
later study used mutually exclusive constructs to show binding of syndapin II to Ig 20 but not 
to an Ig 13-16 construct (73). The mapping of interactions are conducted in non-physiological 
settings and therefore it is not clear whether they occur in vivo (84). This illustrates that a 
combination of different techniques should be used to give confidence to these interactions. 
Aside from the technical issues, the nature of FLNA also introduces some complexity into 




repetitive form with the twenty-four immunoglobulin-like structures permits several interaction 
partners to bind at multiple sites along FLNA. For example, CFTR has been shown to bind Ig 9, 
12, 17, 19, 21, and 23 (62,63). Whether all of these are physiologically relevant, and whether 
binding at Ig 17 is sufficiently critical to be relevant to the pathogenesis of DCD is something 
that needs to be considered. 
Another key consideration is the presence of two other highly homologous proteins in the 
human – filamin B (FLNB)  and filamin C (FLNC). These proteins share the same general 
structure consisting of the N-terminal actin binding domain followed by twenty-four 
immunoglobulin-like repeats which are separated into rod domain-1 and rod domain-2 by the 
two hinge structures (85,86). The three filamins have also been shown to have high amino acid 
sequence homology (>70%) (87). The implication of this is that many interaction partners of 
FLNA also bind one or both of FLNB and FLNC (50). It therefore becomes a bit more difficult 
to determine whether each binding partner really has a functional relationship with FLNA. Note 
that the expression patterns of the three filamins differ (87). This can be used to rule in or rule 
out each filamin isoform as a functionally relevant interaction partner. Co-expression with the 
binding partner of interest, in one or more tissues could mean that the interaction is 
physiologically (or pathologically) relevant. 
Of interest to this project is the interaction of FLNA with the extracellular calcium-sensing 
receptor (CaSR). In 2001, two independent groups identified FLNA to be a binding partner of 
CaSR (67,68). Both groups narrowed down the region of FLNA critical for the interaction using 
a series of truncation and deletion constructs. Awata et al. (68) described the critical region to 
be between Ig 14 to the start of Ig 17 (amino acid residues 1566-1875), while Hjalm et al. (67) 




together, it would be reasonable to assume that the binding site lies within Ig 14-15. Hence, this 
interaction is a candidate for one that is affected by the mis-splicing event observed in DCD. 
1.4 Calcium-Sensing Receptor (CaSR) 
The extracellular calcium-sensing receptor (CaSR) is a G protein-coupled receptor (GPCR) that 
is highly expressed in the parathyroid gland and the kidney (88). Its expression has also been 
detected in various other organs and tissues throughout the body including bone, pancreas, 
intestine, lung, skin, vasculature, and brain (88). It plays a pivotal role in whole body 
extracellular calcium homeostasis through the control of parathyroid hormone (PTH) release 
from the parathyroid gland and calcium excretion through the kidneys (88). The role of CaSR 
in other organs is less well established; however, emerging evidence has revealed an 
increasingly diverse range of functions for CaSR – from the regulation of neuronal excitability 
to the control of fetal lung development (88–90).  
1.4.1 Diseases associated with CASR 
Pathogenic variants in the gene encoding CaSR have been found to cause several conditions 
that involve the dysregulation of extracellular calcium homeostasis. Normally, a drop in 
extracellular calcium concentration is detected by CaSR expressed in the parathyroid gland and 
this initiates the release of PTH into the bloodstream. This hormone acts to increase 
extracellular calcium through decreasing excretion through the kidney, increasing release from 
bone, and increasing absorption in the gut, thereby restoring calcium homeostasis (see ref. (88) 
for a review on CaSR function in extracellular calcium homeostasis). 
It is therefore not surprising that loss-of-function variants in CASR are responsible for 




hypocalciuric hypercalcemia type 1 (FHH1) (91). This condition is characterised by mild to 
moderate elevations in serum calcium and magnesium, a relative hypocalciuria, and often a 
plasma PTH level that sits within the normal range but is considered high in the context of the 
hypercalcemia (88,92). These findings are often incidental as affected individuals are usually 
asymptomatic (92). Meanwhile, homozygosity or compound heterozygosity for loss-of-
function variants in CASR results in a life-threatening disorder known as neonatal severe 
hyperparathyroidism (NSHPT) (91). Affected individuals have marked hypercalcemia, 
elevated plasma PTH, hypercalciuria (a consequence of the hypercalcemia), and bone 
demineralisation leading to pathological fractures (88,92). 
In contrast, gain-of-function variants in CASR are responsible for hypocalcaemic conditions. 
Germline heterozygosity (and more rarely homozygosity (93,94)) for such variants lead to 
autosomal dominant hypocalcaemia type 1 (ADH1), a condition characterised by moderate 
hypocalcaemia accompanied by maladjusted plasma PTH and urine calcium levels (88,92,95). 
Alterations in the level of CASR expression have been implicated in the pathogenesis of primary 
and secondary hyperparathyroidism, and single nucleotide polymorphisms in this gene have 
been linked to nephrolithiasis (96–99). 
1.4.2 The role of CaSR in bone 
Although the diseases linked to CaSR do not appear to have an impact on bone development or 
maintenance directly (e.g. demineralisation in NSHPT occurs as a consequence of elevated 
PTH), emerging studies in bone cells and animal models have provided insights into the 
possible roles of CaSR in bone biology. 
CaSR is expressed in osteoblasts, osteocytes, osteoclasts, and chondrocytes, albeit variably in 




from studies using knockout mouse models have been difficult to interpret, in part, due to 
confounding from the effects of dysregulated PTH secretion. Initial CaSR null mice displayed 
skeletal abnormalities which were able to be rescued by the elimination of PTH (101–104). 
This seemed to suggest that the skeletal manifestations were mediated through the abnormal 
levels of PTH rather than direct effects of loss of CaSR in bone cells. Note however, that this 
knockout may have been incomplete due to the presence of alternative splicing, although, the 
functionality of this splice form lacking exon 5 in osteoblasts has not been verified (105,106). 
Whether the lack of skeletal phenotype in the double knockout model (Casr-/-;Pth-/-) truly 
indicates the redundancy of CaSR in bone cells is therefore uncertain. Subsequently, an 
osteoblast specific knockout using a different approach and targeting a different exon was 
developed (107). These mice exhibited profound effects on skeletal development, but mild 
PTH-dependent hypercalcemia was also observed (107,108). Again, the extent to which this 
phenotype is mediated by PTH rather than loss of CaSR in bone cells is uncertain. 
A mouse model with a constitutively active CaSR targeted to mature osteoblasts has also been 
generated (109). Here, loss of trabecular bone was observed, which was deemed secondary to 
an increase in osteoclasts due to an increase in RANKL expression by osteoblasts (109). 
Notably, no other changes in osteoblast parameters were observed (109). 
While the last mouse model suggests that the constitutive activity of CaSR has little impact on 
osteoblasts, evidence from in vitro studies suggest otherwise. Numerous studies involving the 
stimulation of CaSR in osteoblasts and related cells (e.g. osteosarcoma cell lines) have reported 
increases in osteoblast recruitment, proliferation, differentiation, and mineralisation (110–112). 
The discrepancies between the in vitro and the whole mouse studies, may well be explained by 




1.4.3 Functional relationship between CaSR and FLNA 
Since the identification of FLNA as an interaction partner of CaSR, the exploration of the 
functional significance of this interaction has revealed an increasingly complex relationship 
between these two proteins. 
The initial reports describing the interaction between CaSR and FLNA demonstrated that the 
interaction was necessary for the CaSR-mediated increase in phosphorylation of extracellular 
signal-regulated protein kinase (ERK1/2; a mitogen-activated kinase (MAPK) that is involved 
in coordinating a diverse range of cellular processes from proliferation to differentiation to 
apoptosis) in response to stimulation with extracellular calcium (67,68). 
The CaSR-FLNA interaction has also been shown to be necessary for extracellular calcium 
induced activity of the serum response element (SRE; a transcriptional regulatory element 
present in promoters of genes which participate in cell cycle regulation) via Gaq, RhoA, and 
RhoGEF lbc (113). As SRE activity has been found to be downstream of ERK1/2 (114), the 
above finding supports the idea that the CaSR-FLNA interaction is necessary for the CaSR-
mediated activation of ERK1/2. 
However, Zhang and Breitwieser (69) found that the CaSR-FLNA interaction was not essential 
for ERK1/2 activation stimulated by extracellular calcium, despite the presence of both CaSR 
and FLNA being necessary. The discrepancy between this study and the previous studies could 
have arisen from the differences in the methods used to disrupt the interaction. The first two 
studies used peptides to block the binding sites on CaSR (67) or FLNA (68), while Zhang and 
Breitwieser (69) utilised truncations of CaSR which were missing the binding site. However, 
Pi et al. (113) used a combination of the above three methods to demonstrate that the interaction 




truncation was not identical to that used by Zhang and Breitwieser (69) different results might 
be expected. 
Note that the CaSR-FLNA interaction is likely to be involved in only some of the pathways 
initiated by CaSR stimulation. This was highlighted in the study by Rey et al. (115), which 
demonstrated that the interaction was necessary for the increase in intracellular calcium 
oscillations observed with stimulation with L-phenylalanine (another CaSR agonist), but not 
extracellular calcium. 
Most studies investigating the interaction between FLNA and CaSR have been conducted using 
CaSR-transfected HEK293 cells and therefore expression levels and cellular context may not 
represent physiologically relevant conditions (67–69,98,113,115). Nevertheless, there have 
also been a few studies using cells with endogenous expression of CaSR and these support the 
idea that this interaction is physiologically and/or pathologically relevant. Among these, Tu et 
al. (116) has shown that calcium stimulation of human neonatal foreskin keratinocytes induces 
interactions between CaSR, RhoA, FLNA, and E-cadherin at the membrane. The CaSR-FLNA 
interaction was necessary for the calcium induced membrane translocation of Rho as well as 
E-cadherin-mediated cell-cell adhesion (116). Here, the scaffolding function of FLNA in CaSR 
signaling appears to be physiologically relevant in keratinocytes. 
FLNA and CaSR also seem to influence the expression and/or stability of each other. In 
HEK293 cells transfected with CaSR, FLNA protects CaSR from degradation (69) and 
increases CaSR mRNA levels (98). Meanwhile, in androgen receptor-deficient prostate cancer 
cell lines, extracellular calcium stimulation resulted in FLNA cleavage at hinge 1, and 
subsequent increase in cell migration via CaSR-p115RhoGEF-calpain dependent pathway (77). 
Note that this was not observed in androgen-sensitive LNCaP prostate cancer cell line (77), 




1.4.4 Possible role of CaSR-FLNA interaction in bone 
Clearly, there are cell and tissue specific factors that influence the relationship between CaSR 
and FLNA. To date, no studies have looked into the involvement of FLNA in CaSR signaling 
in osteoblastic cells. The MAPK pathways activated by CaSR have the potential to induce 
differentiation and mineralisation in osteoblastic cells (see ref. 110 for a review). Tellingly, 
FMD (one of the OPDSD characterized by sclerotic skeletal dysplasia) has been shown to be 
also caused by variants in two genes encoding proteins that function as upstream regulators of 
p38 MAPK (118). These genes are MAP3K7 and TAB2 which encode TAK1 (transforming 
growth factor β-activated kinase) and TAB2 (TAK1-associated binding protein) respectively 
(118). There is considerable phenotypic overlap between the different forms of FMD caused by 
variants in FLNA, MAP3K7, and TAB2, which suggests that the same biochemical pathway is 
affected in all three forms of this condition (119). This pathway is yet to be elucidated but one 
plausible pathway is through CaSR-FLNA-TAK1/TAB2-p38 (Figure 1.6). CaSR stimulation 
in osteoblastic cells has been shown to elicit mitogenic responses via activation of p38 (120), 







Figure 1.6: Proposed CaSR-FLNA-TAK1/TAB2-p38 pathway. Extracellular calcium can stimulate proliferation, 
differentiation, and mineralisation in osteoblasts via CaSR. Yamaguchi et al. (120) has shown that the mitogenic 
response occurs via p38 but the exact pathway is unknown (dashed arrow between CaSR and p38). The 
TAK1/TAB2 signalling complex is a known upstream regulator of p38, as indicated by the solid arrow. FLNA is 
hypothesised to be the intermediate that permits the CaSR initiated activation of the TAK1/TAB2 signalling 
complex (dotted arrow between FLNA and TAK1/TAB2).  
 
Figure created using Microsoft PowerPoint for Mac. 
 
1.5 Aims of study 
The aim of this project was to explore the possible mechanisms by which the mis-spliced form 
of FLNA causes the skeletal dysplasia observed in DCD. Two different approaches were taken 
to achieve this objective. 
The first approach utilised cell models in an attempt to characterise the functional consequences 
of this FLNA variant on osteoblast function. I hypothesised that this variant causes accelerated 
differentiation of osteoblasts and an accompanying increase in mineralisation to produce the 
hyperostotic phenotype. The skeletal manifestations of DCD were considered to be hyperostotic 
for three reasons. Firstly, DCD had been placed into the OPDSD which include other disorders 
that are clearly hyperostotic (e.g. FMD1 presents with progressive skull base sclerosis). 
Secondly, the bony fusions that develop in individuals affected with DCD suggest that 




fractures in individuals affected by DCD, supports the idea that this condition is hyperostotic 
rather than hypoostotic. 
The second approach attempted to elucidate the specific pathway that could be mediating such 
an effect, specifically in reference to the proposed CaSR-FLNA-TAK1/TAB2-p38 pathway. I 
hypothesised that the FLNA variant responsible for DCD would inappropriately activate the 
signaling pathways downstream of CaSR to promote the differentiation of osteoblasts. 
The knowledge gained from this study is hoped to contribute to the advances in our 
understanding of bone biology. This may guide the development of treatments and management 
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Chapter 2 Materials and Methods 
2.1 Ethics 
The work in this thesis was conducted under the approvals MEC/08/08/094 and 13/STH/56 
(Health and Disability Ethics Committee, New Zealand). 
2.2 Cell culture 
2.2.1 Cell lines and culture conditions 
The mouse calvarial pre-osteoblastic cell line MC3T3-E1 subclone 4 was cultured in MEM 
(Minimum Essential Medium, GlutaMAX supplement; Gibco), supplemented with 10% fetal 
bovine serum (FBSF; Moregate Biotech, New Zealand). Differentiation and mineralisation was 
induced by further supplementing the media with 50 μg/mL ascorbic acid (Sigma) and 10 mM 
β-glycerophosphate (Sigma). 
The human immortalised cell lines U2OS (osteosarcoma) and T24 (urinary bladder transitional 
cell carcinoma) were cultured in DMEM (Dulbecco’s Modified Eagle Medium, high glucose, 
pyruvate; Gibco), supplemented with 10% FBSF. Differentiation and mineralisation was 
induced in U2OS cultures by further supplementing the media with 50 μg/mL ascorbic acid 
(Sigma), 10 mM β-glycerophosphate (Sigma), and 0.02 μM dexamethasone (Sigma). 
Primary human fibroblasts were cultured in DMEM (high glucose, pyruvate; Gibco) 
supplemented with 10% FBSF and 1% Pen-Strep (10,000 units penicillin and 10 mg 
streptomycin /mL; Gibco). 
All cells were maintained at 37C in a humidified atmosphere consisting of 5% CO2 in air. 
Media was refreshed every two to three days and passaged as necessary using trypsin-EDTA 
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(0.25%, with phenol red; Gibco) to avoid >80-90% confluency, as determined using phase 
contrast microscopy. 
2.2.2 Cell counting and cell plating 
Media was removed and the adherent cells were detached by incubating in trypsin-EDTA 
(Gibco) for 5 minutes at 37C. Trypsin was deactivated by adding an equal amount of media. 
The cells were pelleted by centrifugation at 250 rcf for 5 minutes, and supernatant discarded to 
remove the trypsin before resuspending in fresh media. Cell counting was conducted by loading 
a 20 μL sample of this cell suspension onto a haemocytometer. Cell counts were made on two 
grids, and the average was used to calculate the concentration of cells. The cell suspension was 
diluted with media accordingly for seeding 24-well or 6-well plates. 
2.3 RNA techniques 
2.3.1 RNA isolation 
RNA was isolated from adherent cells using the NucleoSpin RNA Plus (Machery-Nagel) as per 
the instructions. The RNA was eluted with 30 μL of RNase-free water which was provided in 
the kit. The eluate was passed through the same column a second time to maximise RNA yield. 
RNA concentration and quality measurements were made using NanoDrop One C 
Spectrophotometer (Thermo Scientific). The absorbance ratio Δ260/280 of ~2.0 and Δ260/230 
of ~2.0-2.2 were considered ideal values indicating pure RNA; however, samples outside this 
range were utilised if alternatives were unavailable. RNA isolates were stored at -20C. 
Materials and Methods 
 
29 
2.3.2 DNase treatment of RNA isolate 
RNA isolates to be used for quantitative polymerase chain reaction (qPCR) were DNase treated 
using the TURBO DNA-free kit (Invitrogen) as per the instructions to remove any remnant 
genomic DNA prior to cDNA synthesis. 
2.3.3 Synthesis of cDNA from total RNA 
The primers for cDNA synthesis were first annealed to the isolated RNA by combining 10 μL 
of RNA isolate (15-200 ng/μL), with 1 μL of oligo dT (50 μM; ordered as primers from Sigma-
Aldrich), 1 μL of random primers (100 ng/μL; Invitrogen), 1 μL of dNTPs (20 mM), and 
incubating at 65C for 10 minutes. The samples were then cooled on ice before the addition of 
the next reaction mix: 4 μL of 5X first-strand buffer (Invitrogen), 1 μL of DTT (0.1 M; 
Invitrogen), 1 μL of RNase OUT (Invitrogen), 1 μL of SuperScript III Reverse Transcriptase 
(Invitrogen). The samples were incubated at 25C for 5 minutes, then 50C for 50 minutes, and 
finally 70C for 15 minutes, before being stored in the fridge at 4C. For each batch of cDNA, 
a -RT sample (containing a combination of RNA isolates) was run alongside the other samples 
without the addition of the reverse transcriptase in order to assess for any contamination with 
DNA. 
2.4 Quantitative PCR (qPCR) 
2.4.1 qPCR reaction set up 
All primers used for qPCR were already available in the laboratory, and primer efficiencies had 
already been calculated for all except the mouse filamin A (Flna) primer pair. Primer sequences 
and amplification efficiencies are listed in Appendix A. 
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To calculate the primer efficiencies for the Flna primer pair, standard curves were generated 
using five serial dilutions of cDNA from MC3T3-E1: from 5 ng/μL to 0.008 ng/μL. Each 20 μL 
reaction contained 10 μL of LightCycler 480 SYBR Green I Master mix (Roche), 1 μL forward 
primer (3 μM), 1 μL reverse primer (3 μM), 3 μL of H2O (PCR grade, provided with the master 
mix), and 5 μL of cDNA (1 ng/μL; or 5 ng/μL to 0.008 ng/μL for the standard curve). Each 
reaction was set up in technical duplicates to account for pipetting errors. The cycling 
conditions used on the LightCycler 480 Instrument II (Roche) are indicated in Table 2-1. 
Table 2-1: Cycling conditions for qPCR 
Step Temperature Duration 
Initial denaturation 95C 5 minutes 
45 cycles of: Denaturation 95C 10 seconds 
Annealing 60C 10 seconds 
Extension 72C 10 seconds 
Melting curve 72 – 95C Heat at 0.11C/second 
 
2.4.2 Analysis of qPCR data 
Several quality control measures were taken to ensure the validity of results obtained. Firstly, 
the -RT and no template negative controls were run alongside the samples of interest and 
checked for any amplification to exclude possible contamination. Secondly, melt curve 
genotyping was conducted using the LightCycler 480 software version 1.5.1.62 (121). Samples 
were only accepted for downstream analysis if only a single curve was present because 
additional curves would indicate the presence of off-target amplification. Technical duplicates 
with cycle quantification (Cq) values which differed by greater than 0.5 were also excluded 
from analysis. 
Cycle quantification values from the LightCycler 480 software was imported into qbase+ 
software, version 2.1 (Biogazelle, Zwijnaarde, Belgium - http://www.qbaseplus.com) for 
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analysis. Primer pair specific amplification efficiencies (Appendix A) which were calculated 
using standard curves on LightCycler 480 software, were imputed into qbase+ to be 
incorporated into the calculations. 
The samples were normalised using housekeeping genes to control for any differences in the 
total amount of template initially added to the reaction. Three housekeeping genes (Gapdh, 
Ppia, Rps29) were run for the experiments involving the differentiation of MC3T3-E1, while 
just Gapdh was run for obtaining the preliminary result for shRNA-mediated knockdown of 
Flna. When three housekeeping genes (i.e. reference targets) were run, reference target 
stabilities were checked in qbase+; a geNorm expression stability value (M) of < 0.5 and a 
coefficient of variation (CV) of < 0.2 was considered acceptable. If one housekeeping gene 
deviated from the above parameters, it was removed and normalisation was conducted using 
the remaining two. 
Relative expression levels of the genes of interest (Sp7, Runx2, Col1a1, Flna) were exported 
into Microsoft Excel for statistical analysis, detailed in the next section. 
2.5 Statistical analysis of quantitative data 
Quantitative data obtained from qPCR (section 2.4) or western blotting (section 2.13.2) were 
imported into Microsoft Excel for statistical analysis. Each experiment had technical duplicates 
for which the mean was calculated. Data from three independent repeat experiments were 
combined by scaling and normalising to the baseline (i.e. day 0 of differentiation or vehicle 
treated T24 cells). P-values were calculated using a two-tailed, unpaired t-test. Critical P-values 
for the Western blotting experiments were Bonferroni corrected for multiple testing as two 
different conditions (i.e. calcium and strontium treatments) were being tested. Graphs were 
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drawn using Microsoft Excel for Mac, version 16.16.27, and the error bars represent the 
standard error of the means. 
2.6 Phylogenetic analysis of FLNA sequence 
The search for species in which the last nucleotide of the exon corresponding to exon 31 of 
human FLNA (NM_001110556.1) is not conserved, was conducted using the UCSC genome 
browser (122) conservation track showing Multiz alignment from 100 vertebrate species – 
available from: https://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&g=cons100way. 
Sequences from human and the identified rodent species were downloaded from Ensembl 
version 101 (31) and aligned using the MUSCLE algorithm (123) on MEGA X (124) for further 
inspection. Transcript IDs can be found in Appendix B. 
2.7 Alizarin Red S staining for calcium deposits 
2.7.1 Fixing of cells 
Media was removed from the wells (24-well plates) and the adherent cells were washed by 
adding 0.5 mL of phosphate buffered saline (PBS; Oxoid) and swirling for a few seconds before 
draining. Fixing was then achieved by incubating in 0.5 mL of 4% paraformaldehyde (PFA; 
Sigma) in PBS for 10 minutes at room temperature. The PFA was subsequently drained and 
three more washes with PBS were performed. A final 0.5 mL of PBS was added for storage at 
4C. 
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2.7.2 Alizarin Red S staining 
The cells fixed with PFA were drained of PBS and then incubated with 0.5 mL of 1% Alizarin 
Red S (Sigma) for 20 minutes at room temperature. The wells underwent four washes with PBS 
to remove any non-specific staining before being air dried for 10 minutes at room temperature. 
Staining was inspected with the naked eye and also microscopically using the Olympus IX71 
inverted microscope under bright field with the Olympus TH4-200 halogen light. 
2.8 Antisense oligonucleotide (AON) transfections 
2.8.1 AON design 
Guidelines for antisense oligonucleotide (AON) design as described by Aartsma-Rus (125) 
were taken into account when designing the following AONs. The secondary structure of the 
region of interest was evaluated using RNAfold (http://rna.tbi.univie.ac.at/cgi-bin/RNAWeb-
Suite/RNAfold.cgi) (126). The locations of predicted exonic splicing enhancers were 
determined by Human Splicing Finder (http://www.umd.be/HSF/) (127). Calculation of the free 
energy of the AONs, AON-AON complexes, and the binding energy of the AON and its target 
sequence, was carried out on RNAstructure (http://rna.urmc.rochester.edu/RNAstructureWeb/) 
(128). 
AON sequences are shown in Table 2-2 below. All were made with 2’-O-methyl RNA 
phosphorothioate modified bases. Scramble AON was already available in the laboratory, and 
were ordered from TriLink BioTechnologies. The new AONs were ordered dry with desalt-
only purification from Sigma-Aldrich. 
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Table 2-2: AON sequences 
Name Sequence 
mAON 1 AUCCUUGGCCUCUUCUCACU 
mAON 2 CACCCAUCCUUGGCCUCUUC 
hAON 1 ACCCCCCACCCCUCCUCACC 
hAON 2 GACCUACCCCCCACCCCUCC 
Scramble CCUCUUACCUCAGUUACAAUUUAUA 
 
2.8.2 AON transfection 
AONs were resuspended in Milli-Q purified water. A 10 μM working solution was made and 
stored at -20 C. Transfections mixes were made by combining 50 μL of Opti-MEM (Gibco) 
containing 1-20 μL of AON (10 μM working solution), with another 50 μL of Opti-MEM 
containing 2 μL of Lipofectamine 2000 (Invitrogen) for each well to be transfected. Mixes were 
incubated for at least 5 minutes at room temperature to allow the lipid-RNA complexes to form. 
Cells were seeded in 24-well plates at a density of 1 x 105 cells/well in 0.5 mL media and 
allowed to adhere for 24 hours. The media was refreshed prior to the addition of the 100 μL 
transfection mixes. Transfected cells were incubated at 37C in 5% CO2 for 24 hours, then cell 
lysates were harvested for RNA as described in section 2.3.1. The RNA isolate was used for 
cDNA synthesis (section 2.3.3) for subsequent reverse transcription polymerase chain reaction 
(RT-PCR; detailed in section 2.9) to identify transcripts representing alternative splicing events. 
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2.9 Polymerase chain reaction (PCR) 
2.9.1 RT-PCR primer design 
Primers for reverse transcription polymerase chain reaction (RT-PCR) were designed to flank 
exon-exon junctions so that it was possible to distinguish between amplification from cDNA 
and genomic DNA. Primer3web version 4.1.0 (http://primer3.ut.ee) was used to select the 
following optimal parameters: length of 20 bases, Tm of 60C, and product size of 150-350. 
Complementarity and specificity were checked using the UCSC In-Silico PCR tool 
(https://genome.ucsc.edu/cgi-bin/hgPcr). All primers were ordered dry from Sigma-Aldrich 
with desalt-only purification. These were rehydrated with Milli-Q purified water to make 
100 μM stock solutions which were subsequently stored at -20C. From these 100 μM stock 
solutions, 10 μM working solutions were made by further dilution with Milli-Q purified water 
and these were stored at 4C. See Appendix C for RT-PCR primer sequences, product sizes, 
and optimised cycling conditions for each primer pair. 
2.9.2 PCR reaction 
PCR reactions were carried out by combining 0.8 μL of cDNA (as prepared in 2.3.3 and diluted 
to 10-20 ng/μL) with 0.8 μL each of the forward and reverse primers (10 μM as prepared in 
2.9.1), 1 μL of GeneAmp 10X PCR Gold Buffer (Applied Biosystems), 0.6 μL of 25 mM 
MgCl2 solution (Applied Biosystems), 0.1 μL of dNTPs (20 mM solution), 0.05 μL of 
AmpliTaq Gold DNA Polymerase (Applied Biosystems) and 5.85 μL of Milli-Q purified water. 
A blank was run without the addition of cDNA to serve as a negative control. See Table 2-3 
and Table 2-4 for cycling temperatures for the standard and touchdown programs respectively. 
Some primers required the addition of 2 μL of combined enhancer solution (2.7 M betaine 
[Sigma], 20 nM DTT [Sigma], 55 ng/mL bovine serum albumin [Sigma], 6.7% dimethyl 
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sulfoxide [Sigma], in Milli-Q purified water) which replaced 2 μL of the Milli-Q purified water 
from the 10 μL PCR reaction mixture. 
Table 2-3: Standard thermal cycling conditions for PCR 
Step Temperature Duration 
Initial denaturation 94C 10 minutes 
35 cycles of: Denaturation 95C 1 minute 
Annealing 65C 1 minute 
Extension 72C 1 minute 
Final extension 72C 10 minutes 
Hold 10C Until transferred to 4C storage 
 
Table 2-4: Touchdown program thermal cycling conditions for PCR 
Step Temperature Duration 
Initial denaturation 94C 10 minutes 
3 cycles of: Denaturation 94C 30 seconds 
Annealing 65C 30 seconds 
Extension 72C 1 minute 
3 cycles of: Denaturation 94C 30 seconds 
Annealing 62C 30 seconds 
Extension 72C 1 minute 
3 cycles of: Denaturation 94C 30 seconds 
Annealing 59C 30 seconds 
Extension 72C 1 minute 
36 cycles of: Denaturation 94C 30 seconds 
Annealing 56C 30 seconds 
Extension 72C 1 minute 
Final extension 72C 10 minutes 
Hold 10C Until transferred to 4C storage 
 
2.9.3 Gel electrophoresis 
PCR products were visualised and product sizes estimated using gel electrophoresis. A 1-2% 
gel was made by dissolving 1-2 g of agarose (HydraGene) in 100 mL of TBE buffer solution 
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(1.08 g/L UltraPure Tris Buffer [Invitrogen], 0.55 g/L boric acid [LabServ, ThermoFisher], 
0.093 g/L EDTA [Sigma], in 100 mL distilled water). 3 μL of PCR product was combined with 
1.5 μL of SYBR Green I Nucleic Acid Gel Stain (1:2000 dilution; Invitrogen) and run at 96 V 
for 15-60 minutes alongside 0.5 μL of 100 bp or 1 kb ladder (New England Biolabs; NEB) also 
combined with 1.5 μL of SYBR. Gels were imaged under UV light using FireReader V4 
(UVITEC, Cambridge, UK). 
2.10 Sanger sequencing 
2.10.1 Pre-sequencing reaction for clean-up of PCR products 
PCR products were prepared for Sanger sequencing by removing residual dNTPs and primers 
through the following pre-sequencing reaction: 4 μL of PCR product was combined with 2 μL 
of shrimp alkaline phosphatase (E70092, Cytiva), 0.6 μL of exonuclease I (NEB), 7.5 μL 
Milli-Q purified water. This mixture was incubated at 37C for 15 minutes, then at 80C for 20 
minutes, and then held at 10C until used for the BigDye Terminator reaction or transferred to 
storage at 4C. 
2.10.2 Sequencing reaction (BigDye Terminator) 
For the sequencing of PCR amplified products, 7 μL of the pre-sequencing reaction (described 
in 2.10.1) was combined with 2 μL of BigDye Terminator v3.1 Ready Reaction Mix (Applied 
Biosystems), 1 μL of BigDye Sequencing Buffer (Applied Biosystems), and 0.64 μL of the 
relevant forward or reverse primer (10 μM working solution). 
For the sequencing of plasmids, 1 μL of extracted plasmid (preparation described in 2.11.3) 
was combined with 2 μL of BigDye Terminator v3.1 Ready Reaction Mix, 1 μL of BigDye 
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Sequencing Buffer, 5 μL of Milli-Q purified water, and 1 μL of the relevant forward or reverse 
primer (10 μM working solution). Table 2-5 shows the thermal cycling conditions. 
Table 2-5: BigDye Terminator thermal cycling conditions 
Step Temperature Duration 
Initial denaturation 96C 1 minute 15 seconds 
25 cycles of: Denaturation 96C 45 seconds 
Annealing 50C 45 seconds 
Extension 60C 3 minutes 30 seconds 
Hold 10C Until transferred to 4C storage 
 
2.10.3 Clean-up of sequencing reaction 
Unincorporated dideoxynucleotide triphosphates (ddNTPs) were removed from products of the 
BigDye Terminator reaction by ethanol precipitation of the sequencing products. 2 μL of 3 M 
sodium acetate (Sigma), 10 μL of Milli-Q purified water, and 50 μL of 96% ethanol (Lab 
Supply) was added to 10 μL of the sequencing product. This mixture was incubated at room 
temperature for 15 minutes and subsequently centrifuged at 3220 rcf for 20 minutes. 
Supernatant was removed and the pellet was washed with ethanol by adding 150 μL of 70% 
ethanol and centrifuging at 3220 rcf for 10 minutes. The ethanol wash was repeated once more. 
The supernatant was removed and the pellet left to air dry at room temperature for 
approximately 40 minutes. 
2.10.4 Sequencing service 
The ethanol precipitated sequencing products were submitted to Genetic Analysis Services, 
University of Otago, for capillary sequencing using the 3730xl DNA Analyzer (Applied 
Biosystems). 
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2.10.5 Sequence analysis 
Sequencing results were received as .abi files and electropherograms were visualised and 
analysed using the Sequencher software version 5.4 (Gene Codes Corporation, USA). 
2.11 Cloning techniques 
2.11.1 Ligation, transformation, and culture with the pGEM-T vector 
PCR products were inserted into the pGEM-T vector (Promega) with the following reaction: 
1-3 μL of PCR product was combined with 5 μL of 2X Rapid Ligation Buffer (Promega), 1 μL 
of pGEM-T vector (Promega), 1 μL of T4 DNA Ligase (Promega), and 0-2 μL Milli-Q purified 
water. The reaction mixture was incubated at room temperature for 1 hour. Transformation of 
100 μL of chemically competent E. coli was carried out by adding 5 μL of the ligation mix and 
incubating at room temperature for 1 hour. Following this, 100 μL of the transformation culture 
was spread on agar plates containing carbenicillin (100 μg/mL; Sigma) and incubated at 37C 
overnight. Agar plates showing colonies were subsequently stored at 4C. 
2.11.2 Lysogeny broth culture 
Lysogeny broth (LB) for bacterial culture was prepared by dissolving two LB medium capsules 
(3002-041, MP Biomedicals), 2.4 g of bacteriological peptone (Oxoid), and 1.2 g of BD Bacto 
yeast extract (BD biosciences) in 320 mL of distilled water. This solution was sterilised in an 
autoclave at 121C for 30 minutes and subsequently stored at room temperature. 
Colonies were picked from agar plates using autoclave-sterilised toothpicks and inoculated into 
3 mL LB for small plasmid preparation (minipreps) or 100 mL LB for large plasmid 
preparations (midipreps). For plasmids with ampicillin selection (pGEM-T plasmid), 
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carbenicillin (Sigma) was added immediately to a final concentration of 100 μg/mL. For 
plasmids with kanamycin selection (dual expression plasmid), inoculated cultures were 
incubated at 37C with agitation for one hour prior to the addition of kanamycin (Sigma) for a 
final concentration of 50 μg/mL. Cultures were incubated at 37C with agitation and grown to 
saturation (typically overnight). 
The cultures were then centrifuged at 3220 rcf for 20 minutes. The supernatant was discarded, 
and the pelleted E. coli were stored at 4C. 
2.11.3 Plasmid DNA purification 
Plasmid DNA purification was carried out using the NucleoSpin Plasmid kit (Machery- Nagel) 
or NucleoBond Xtra Midi (Machery-Nagel) according to the provided protocols, for mini- and 
midipreps respectively. For the midipreps, precipitated DNA was resuspended in 400 μL of 
Milli-Q purified water and left to dissolve thoroughly overnight at 4C before quantification to 
obtain an accurate measurement. The quality and quantity of the purified plasmid was verified 
using the NanoDrop One C Spectrophotometer (Thermo Scientific). 
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Figure 2.1: Construction of the shRNA-eGFP dual expression plasmid. hU6 promotor and eGFP fragments were 
produced by PCR amplification (forward and reverse arrows). Restriction enzymes are indicated in purple above 
scissor symbols. CMV, cytomegalovirus mammalian expression promoter; eGFP, enhanced green fluorescent 
protein; shRNA, short hairpin RNA. 
 
Figure created using Microsoft PowerPoint for Mac. 
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2.12.1 Digestion of the vector 
PSF-CMV-CMV-SBFI dual CMV expression plasmid provided the backbone for the 
production of the shRNA-eGFP construct. The original vector which had already been digested 
with PvuI and EcoRV restriction enzymes, was available in the laboratory. 
Subsequent digestion of the plasmid in which the hU6 promotor and shRNA sequences had 
been added, was conducted using SalI restriction enzyme. For the digestion reaction, 1 μg of 
plasmid was combined with 5 μL of 10X CutSmart Buffer (NEB) and 20 units (1 μL) of 
SalI-HF (NEB), and made up to a final volume of 50 μL with Milli-Q purified water. This 
mixture was incubated at 37C for 1 hour, then subsequently stored at 4C. 
2.12.2 Design and production of shRNA fragments 
The sequence for shRNA1 which targets the 3’UTR of mouse Flna was obtained from the 
Sigma-Aldrich website under the clone ID: NM_010227.2-8049s21c1. The sequence for 
shRNA2, which targets the 5’UTR of mouse Flna was designed using BLOCK-iT RNAi 
Designer (available at: https://rnaidesigner.thermofisher.com/rnaiexpress/). The accession 
number NM_010227.3 was used to search for targets in the 5’UTR using the default settings. 
The highest ranking sequence was chosen. The sequences of shRNA1 and shRNA2 are shown 
in Table 2-6 along with shRNA consisting of scramble sequence (shRNAscr) that had 
previously been incorporated into the dual expression plasmid by another member of the lab. 
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Overhang sequences were added to the 5’ and 3’ ends of shRNA1 and shRNA2 to facilitate 
HiFi assembly. The 5’ overhang consisted of the final twenty nucleotides of the hU6 promoter 
sequence, while the 3’ overhang consisted of the first twenty nucleotides following the EcoRV 
cut site in the PSF-CMV-CMV-SBFI vector. The forward and reverse strands of the complete 
sequence for shRNA1 and shRNA2 with the overhangs were ordered as oligos from 
Sigma-Aldrich, in a dry format with desalt-only purification. Sequences of these oligos are 
listed in Appendix D. These were resuspended to 100 μM with Milli-Q purified water and 
stored at -20C. 
The forward and reverse oligos for each shRNA were annealed to produce double stranded 
fragments. An annealing buffer composed of 10 mM UltraPure Tris Buffer (Invitrogen) and 
50 mM NaCl (Merck) in distilled water was adjusted to pH 7.5 by the addition of HCl (ACS 
reagent 37%; Sigma). The oligos were added to the annealing buffer to a final concentration of 
1 pmol/μL. This solution was heated to 95C for 5 minutes, then incubated at 92C for 2 
minutes, 89C for 2 minutes, and so on (drop 3C every 2 minutes), until 23C was reached, 
after which it was stored at 4C. 
2.12.3 Q5 PCR amplification of hU6 and eGFP fragments 
Primers to amplify hU6 promotor and eGFP (enhanced green fluorescent protein) sequences 
were available in the laboratory. However, the reverse primer for amplifying hU6 needed to be 
ordered new so that overhangs matching the first twenty bases of shRNA1 and shRNA2 could 
be added to facilitate HiFi assembly. These primers were ordered from Sigma-Aldrich in a dry 
format with desalt-only purification. 
Q5 High-Fidelity DNA polymerase (NEB) was used for PCR amplification of the hU6 and 
eGFP fragments. Reactions were made to a final volume of 10 μL according to the 
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accompanying protocol, with 1 ng of plasmid DNA (another shRNA-eGFP plasmid available 
in the laboratory) serving as the template for both the hU6 and eGFP fragments. A touchdown 
program was utilised for this reaction (Table 2-7). The primers used for the PCR reactions are 
listed in Appendix D. 
Table 2-7: Touchdown thermal cycling conditions for Q5 PCR 
Step Temperature Duration 
Initial denaturation 98C 30 seconds 
3 cycles of: Denaturation 98C 10 seconds 
Annealing 65C 30 seconds 
Extension 72C 15 seconds 
3 cycles of: Denaturation 98C 10 seconds 
Annealing 62C 30 seconds 
Extension 72C 15 seconds 
3 cycles of: Denaturation 98C 10 seconds 
Annealing 59C 30 seconds 
Extension 72C 15 seconds 
36 cycles of: Denaturation 98C 10 seconds 
Annealing 56C 30 seconds 
Extension 72C 15 seconds 
Hold 10C Until transferred to 4C storage 
 
PCR products were visualised using gel electrophoresis, as described in section 2.9.3. 1 μL of 
PCR product was combined with 1 μL of SYBR and run alongside 1 μL of 100 bp ladder (NEB) 
also combined with 1 μL of SYBR. Gels were checked to confirm the presence of a band of the 
appropriate size and the absence of extra bands that would indicate the presence of off-target 
amplification. PCR products were quantified by measuring the intensity of the band compared 
to the 100 bp ladder using the ImageJ software, version 1.53a (129). 
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2.12.4 HiFi assembly of plasmids 
NEBuilder HiFi DNA Assembly (NEB) was used according to the accompanying protocol to 
assemble the DNA fragments with the cut vector. Initially a vector:insert ratio of 1:5 was used 
as suggested by the protocol but this yielded no colonies and subsequently higher 
concentrations of insert (hU6, shRNA, eGFP) were trialled and found to achieve more efficient 
assembly. Table 2-8 shows the amounts of vector and insert used for a 5 μL assembly reaction. 
Reactions mixes were incubated at 50C for 1 hour, and subsequently stored at -20C or used 
immediately for transformation of chemically competent E. coli as described in section 2.11.1. 
Transformed cells were grown overnight on agar plates containing kanamycin at 50 μg/mL. 
Table 2-8: Amounts of vector and insert added to a 5 μL assembly reaction 
 shRNA1 shRNA2  shRNA-
eGFP 
pSF.CMV.CMV.sbfI 
digested with PvuI and 
EcoRV (Vector) 
0.009 pmol 0.009 pmol pSF.hU6-
shRNA.CMV.sbfI 
digested with SalI 
(Vector) 
0.007 pmol 
hU6 (PCR) 1.362 pmol 1.385 pmol eGFP (PCR) 0.209 pmol 
shRNA (Annealed) 0.500 pmol 0.500 pmol   
 
2.12.5 Colony PCR 
Colony PCR was used to identify transformants with the correctly assembled plasmid. Initially, 
four colonies were picked using autoclave-sterilised toothpicks to add into PCR reaction mixes, 
made as described in section 2.9.2. Reactions were carried out using the standard cycling 
conditions as described in Table 2-3. Primers used for this purpose were available in the 
laboratory and are listed in Appendix D. 
PCR products were run on a gel (section 2.9.3), and product sizes were used to determine 
whether the plasmid had assembled correctly. If none of the colonies picked were deemed to 
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have the correct plasmid, then further colonies were picked for colony PCR. If this did not yield 
any positive colonies, then optimisation of the assembly step was conducted. 
Colonies which were positive for correct insert on colony PCR, were then grown in LB culture 
for plasmid DNA purification (miniprep; section 2.11.2 and 2.11.3). These plasmids were 
sequenced (section 2.10) to verify correct assembly and absence of any unwanted mutations. 
Primers used for sequencing the plasmids were available in the laboratory and are listed in 
Appendix D. 
Plasmids with the correct sequence were reproduced at a larger quantity by first transforming 
chemically competent E. coli with the miniprep and growing them overnight on kanamycin 
selective agar. A single colony was picked to be inoculated into a 100 mL of LB culture 
containing kanamycin, to be grown to saturation for subsequent plasmid purification (midiprep; 
section 2.11.2 and 2.11.3). 
2.12.6 Plasmid transfections 
Initially forward transfections were trialled. MC3T3-E1 cells were seeded in 24-well plates at 
a density of 5 x 104 cells/well in 0.5 mL media and allowed to adhere for 24 hours. The media 
in each well was refreshed prior to the addition of transfection mixes containing 400 ng of 
plasmid DNA in 50 μL of Opti-MEM (Gibco) combined with 2 μL of Lipofectamine 2000 
(Invitrogen) in 50 μL of Opti-MEM.  
Transfected cells were incubated at 37C in 5% CO2 and transfection efficiency was monitored 
at 24, 48, and 72 hours using the Olympus IX71 inverted microscope under fluorescence (green 
filter) with the X-cite series 120Q (Lumen Dynamics) and bright field with Olympus TH4-200 
halogen light. Photographs were taken using the Olympus DP71 camera and the cellSens 
software version 2.3 (Olympus). 
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Subsequently, a modified reverse transfection procedure was adopted. MC3T3-E1 cells were 
seeded into 24-well plates at confluence (~1.5 x 105 cells/well) in 0.5 mL media and 
transfection mixes immediately added. Transfected cells were incubated at 37C in 5% CO2 for 
five to six hours before being subcultured into four wells to allow room for growth. The 
subculturing process involved the removal of media then the addition of 100 μL of Trypsin-
EDTA (0.25%, with phenol red; Gibco) to detach the cells. Once the cells had detached (after 
~5 mins), the trypsin was neutralised with the addition of 1.9 mL of media. Cells were mixed 
into this volume by pipetting and this cell suspension was distributed to four wells, each with 
0.5 mL. Transfection efficiency was monitored as described above, at 24, 48, and 72 hours post 
the transfection procedure. 
Experiments which yielded transfection efficiencies of >30% were lysed for RNA and 
subsequent qPCR to determine mRNA levels of Flna as described in section 2.3 and 2.4. 
2.13 CaSR stimulation and measurement of MAPK activation 
2.13.1 Calcium and strontium treatment of T24 cells 
1 M CaCl2 and SrCl2 stock solutions were made by dissolving calcium chloride (dihydrate, 
ACS; BDH, United Arab Emirates) and strontium chloride (anhydrous; Sigma) respectively in 
Milli-Q purified water. This was added to media (DMEM + 10% FBSF, see section 2.2.1) to 
achieve a final concentration of 10 mM CaCl2 or SrCl2 in the treatment media. Vehicle control 
media was made up by adding the same volume of Milli-Q purified water to media. 
T24 cells were seeded at 5 x 104 cells/well in 24-well plates in 0.5 mL media and incubated for 
24 hours at 37C in 5% CO2 to allow the cells to adhere prior to the experiment. Each 
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experimental condition (i.e. vehicle, CaCl2, and SrCl2 treatment) was set up with duplicate 
wells. 
For the treatment, media was replaced with treatment or vehicle control media and the cells 
were incubated at 37C in 5% CO2 for 10 minutes. The cells were then immediately placed on 
ice and media was replaced with 100 μL of lysis buffer made up of 1% Triton X-100 (Fisher 
Scientific) in a solution containing protease and phosphatase inhibitors (cOmplete Mini, 
EDTA-free, protease inhibitor cocktail and phosSTOP; Roche) in PBS (Oxoid). Cell lysates 
were stored at -20C or used immediately for western blotting. 
2.13.2 Western blotting analysis 
Protein in the cell lysates were denatured by combining 25 μL of lysate with 5 μL of 6X 
denaturing-SDS loading dye (Appendix E) at 95C for 5 minutes. 25 μL of the denatured protein 
was loaded onto a 10% polyacrylamide gel containing 0.1% SDS (Appendix E) in a 
Tris/Glycine running buffer containing 0.1% SDS (Appendix E). Proteins were separated by 
size using electrophoresis conducted at 200 V for 30 minutes. 
Resolved proteins were then transferred onto a nitrocellulose membrane (0.2 μm pores, 
Bio-Rad) in a Tris/Glycine transfer buffer containing 10% isopropanol (Appendix E), using the 
Trans-Blot Turbo transfer system (12 V for 10 minutes followed by 25 V for 30 minutes). 
Membranes were blocked in Odyssey blocking buffer (PBS; LI-COR) for 1 hour at room 
temperature. 
Incubation with primary antibodies was conducted overnight at 4C in 50% Odyssey blocking 
buffer diluted in PBS. Anti p38 (rabbit, Cell Signaling Technology [CST] #9212), anti p-p38 
(mouse, CST #9216), anti ERK1/2 (rabbit, CST #9102), and anti p-ERK1/2 (mouse, CST 
#9106) were all used at 1:1000. 
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Membranes were briefly rinsed in PBS before incubating with secondary antibody for 1 hour 
at room temperature. IRDye 800CW goat anti-mouse (926-32210, LI-COR) and IRDye 680CW 
goat anti-rabbit (926-68071, LI-COR) were used at 1:25000 in 5% non-fat milk powder (Pams) 
in PBS. 
Membranes were washed three times with PBS for 5 minutes and dried prior to visualisation 
on Odyssey CLx imaging system (LI-COR). Image Studio Lite software version 5.2.5 
(LI-COR), was used to quantify the bands relative to the background above and below the band. 











Chapter 3 Results 
3.1 Investigating the effects of DCD-FLNA on osteoblast function 
3.1.1 Introduction 
Digitocutaneous dysplasia (DCD) is caused by a single mis-splicing event in FLNA. This results 
in the deletion of sixteen amino acids from the encoded filamin A protein (FLNA; 
NP_001104026.1:p.Val1724_Thr1739del) (16). This FLNA variant (referred to as DCD-FLNA 
from here on) evidently has an impact on the normal development of the skeleton, yet, how this 
is mediated remains unclear (3). 
Abnormal development of bone can result from the dysregulation of one or both of bone 
deposition and bone resorption (1). These processes are controlled by three main cell types: 
bone-building osteoblasts, bone-resorbing osteoclasts, and mature osteocytes which monitor 
and modify the bone tissue they are embedded within – either directly, or indirectly by 
coordinating the activities of local osteoblasts and osteoclasts (1). While DCD-FLNA may be 
disrupting the function of any or all of these cell types, the work in this section is focused on 
the possible effects on osteoblasts. This is to address the hypothesis that the bony defects are 
mediated by the dysregulated activity of osteoblasts. 
The study of genetic diseases is commonly conducted using patient cell lines. However, this 
was not feasible in this context for two reasons. Firstly, the rarity of this disease and the type 
of cell desired (osteoblasts) made inaccessibility an issue. Secondly, any cells sampled from 
patients could not be guaranteed to express the disease allele due to the extremely skewed 




a method by which we could introduce the mutation or the expression of DCD-FLNA into an 
established osteoblastic cell line. 
The first step required was to identify a suitable cell line to model osteoblasts. It was important 
that this cell line was able to model the early stages of differentiation. This was necessary so 
that I could test the hypothesis that DCD-FLNA would induce accelerated differentiation and 
increased mineralization. Subsequently, methods to introduce the expression of DCD-FLNA 
into the chosen cell line were developed and optimised.  
3.1.2 MC3T3-E1 differentiation can be examined using Sp7 and Runx2 
MC3T3-E1 is an immortalised pre-osteoblastic cell line initially isolated from the calvarium of 
a newborn mouse (130), and is widely used to study the factors that influence osteoblastic 
differentiation (131). Osteoblastic differentiation associated with collagen matrix deposition 
can be induced by stimulating these cells with ascorbic acid (132). Meanwhile, supplementation 
with organic phosphates enables the matured matrix to be mineralised (133,134). 
To identify markers suitable for monitoring the early stages of osteoblastic differentiation in 
MC3T3-E1, gene expression was measured following treatment with ascorbic acid and 
β-glycerophosphate. Cells were seeded in 24-well plates at a density of 5 x 104 cells/well and 
allowed to adhere for 24 hours. Media was subsequently changed to differentiation media 
containing 50 μg/mL ascorbic acid and 10 mM β-glycerophosphate, and this time point was 
assigned as day 0. Samples were subsequently collected at 24 hour intervals over six days in 
culture with differentiation media. Quantitative PCR (qPCR) was used to measure the 
expression levels of three genes associated with osteoblast differentiation and mineralisation: 




(135,136), while Col1a1 encodes a component of type I collagen and is commonly used as an 
osteoblast-specific marker (137). 
An increase in the expression of Sp7 and Runx2 was observed from day two in differentiation 
media. This increase was found to be statistically significant (P < 0.05) in unpaired, two tailed 
t-tests comparing each time point to the baseline at day 0. While there was a slight increase in 
the expression of Col1a1 over the course of treatment with differentiation media, this was not 
statistically significant (Figure 3.1). 
The results here indicate that Sp7 and Runx2 can be used as markers of osteoblastic 
differentiation in the MC3T3-E1 cell line. These can be used to measure the impact of 









Figure 3.1: Expression levels of osteoblast markers in MC3T3-E1 as measured using qPCR following treatment 
with differentiation media for six days. There was a significant increase in the mRNA expression of Sp7 and Runx2 
from day 2 while the increase in Col1a1 was not found to be significant. Expression levels are described as fold 
change relative to baseline at day 0. Data was combined from three independent repeats (n = 3). Error bars indicate 
standard error of the means. *P < 0.05; **P < 0.01; calculated using an unpaired, two tailed t-test. 
 
3.1.3 Mus musculus has the DCD variant in Flna but exhibits normal splicing 
In the previous section, the MC3T3-E1 cell line was confirmed to have the necessary attributes 
to model the process of osteoblastic differentiation. However, the fact that it was derived from 
another species was something that needed to be considered. This was especially pertinent 































































































nucleotide was not conserved in rodents (16). Accordingly, the genetic sequence encoding 
filamin A in mouse was compared to that of human to examine the differences that were present. 
The reference sequences for human FLNA and mouse Flna1 were obtained from Ensembl 
version 101 (31) and aligned to facilitate the identification of such differences. The final base 
of mouse exon 30 (corresponding to human exon 31) was found to be an adenine – the same as 
the disease allele responsible for DCD in humans (Figure 3.2). Other sequence differences were 
also observed in this region and these are highlighted using red font in Figure 3.2. These 
differences were much more common in the intronic sequences. This latter observation was not 
unexpected given that introns are typically not well conserved compared to exons (138). 
  
                   (human exon 31)                                      (human intron 31) 
                     * 
Human: CAACAGCCCC TTCCAAGTGACGgtgaggaggggtggggggta 
                     . 
Mouse: CAACAGCCCCTTCCAAGT TACAgtgagaagaggccaaggatg 
                     . 
                    (mouse exon 30)                                       (mouse intron 30) 
 
  
Figure 3.2: Alignment of the human FLNA and mouse Flna sequences flanking the position of the recurrent DCD 
variant. Sequence from the end of human exon 31 and the start of the following intron is shown with the equivalent 
mouse exon 30 and its following intron. The final nucleotide of human FLNA exon 31 corresponding to the position 
of the recurrent G>A variant, is highlighted in yellow. The equivalent position in mouse is occupied by an adenine. 
Exonic sequences are in capitals and in black font while intronic sequences are in lower case and in dark blue. The 
nucleotides in the mouse sequence which differ from the human sequence are highlighted in red font. 
 
In humans, the presence of an adenine at the last nucleotide of exon 31 is disruptive to normal 
splicing of this exon, as demonstrated in DCD. Whether the presence of an adenine at the 
equivalent position in mouse Flna would have the same effect was clearly an important question. 
There was a possibility that DCD-FLNA could in fact be a physiological isoform of FLNA in 
 
 
1 Transcript IDs: ENST00000369850.10 (Homo sapiens) and ENSMUST00000033699.12 (Mus musculus) 




the mouse. In that case, cells derived from mice would not be suitable for investigating how 
DCD-FLNA causes disease in humans. 
A publicly available mouse organ development RNA-seq datasets from the Wold lab, Caltech 
(139), was used to investigate this (with help from Dr Greg Gimenez, Department of Pathology, 
University of Otago). Rare, non-canonical alternative splicing events that utilised cryptic donor 
splice sites within mouse exon 30 (i.e. events that were potentially analogous to the mis-splicing 
event observed in DCD) were searched for by identifying split reads spanning from inside of 
exon 30 to the start of exon 31. 
A total of 17 reads representing 3 potential cryptic splice sites in mouse exon 30 were identified. 
Eleven reads utilised a cryptic splice site located six nucleotides 5’ to the original splice site 
(position -6; the last nucleotide of the exon being position -1), while 1 read utilised a site located 
forty-eight nucleotides from the original site (position -48; analogous to that observed in DCD), 
and the remaining 5 reads utilised a site that was located 132 nucleotides away (position -132) 
(Figure 3.3A).  The levels at which these three events were observed were minimal compared 
to the >7600 reads mapping to the canonical junction between the end of exon 30 and start of 
exon 31 (Figure 3.3B). These mis-splicing events were considered to be background noise and 
not physiologically or pathologically relevant. The presence of an adenine at the last nucleotide 
of this exon did not appear have a detrimental effect on the normal splicing of this exon-intron 
junction in Mus musculus.  
It was judged that, while the nucleotide variant itself cannot be studied in MC3T3-E1, the 
protein consequences (i.e. the deletion of the 16 amino acids in FLNA) should still be able to 











          
 
Figure 3.3: Alternative splicing events involving mouse Flna exon 30 that were identified in the mouse organ 
development RNA-seq data. (A) Three different cryptic donor splice sites were identified at 6, 48, and 132 
nucleotides 5’ to the original donor site. (B) Number of reads for the splicing events depicted in (A) are shown in 
the graph on the left. The graph on the right shows only the mis-splicing events with an adjusted scale. 
 
3.1.4 Other species in the order Rodentia also have the DCD variant 
The wild type allele of the mouse Flna contains a G>A transition (compared to the orthologous 
human site) which is equivalent to the recurrent DCD variant. In humans, this variant causes 
mis-splicing at this splice site, but no evidence of such mis-splicing was found in mice. There 
must be some differences between mouse and human in the regulation of splicing at this site to 
account for this observation. 
Such differences may reside in cis-acting sequence features or trans-acting splicing regulatory 










































sequences in this region (a small section is shown in Figure 3.2). However, with this strategy, 
there was no ability to differentiate between sequence differences which had some role in 
influencing splicing at this exon, and those that were simply a result of genetic divergence since 
the last mouse-human common ancestor, ~87 million years ago (140). Thus, a phylogenetic 
approach was taken. 
A search was conducted to identify further species that carried the equivalent of the recurrent 
DCD variant (i.e. an adenine at the last nucleotide of the exon corresponding to human exon 31 
of FLNA). The UCSC genome browser (http://genome.ucsc.edu) (122), with the conservation 
track (Vertebrate Multiz Alignment) was used to examine this nucleotide position in 100 
vertebrate species. This nucleotide position was found to be highly conserved over a wide range 
of species; however, the same G>A transition was observed in a total of nine species belonging 
to the order Rodentia (branches highlighted in red in Figure 3.4). This was consistent with what 
had been reported by Sun et al. (16). The chinchilla, although part of the order Rodentia, did 
not have the G>A transition indicating that a reversion event had likely taken place. The only 
other species in this group of 100 vertebrates in which this nucleotide was not conserved was 
the spotted gar, which instead had a G>T transversion (highlighted in blue in Figure 3.4). 
Subsequently, the sequences of the nine species of rodent were aligned with exon and intron 31 
of human FLNA, as shown in Figure 3.5. Sequences were obtained from Ensembl version 101 
(31), transcript IDs can be found in Appendix B. Nucleotides which differed from human but 
were the same in this group of rodents (i.e. changes that were co-inherited with the G>A 
transition equivalent to the recurrent DCD variant) are boxed in orange: one was found in the 
exonic sequence, and a further eleven in the intronic sequence. These were considered as 





The finding of differences between rodents and human highlighted how interspecific 
differences could potentially generate further issues in experiments utilising the MC3T3-E1 
cell line. This prompted the search for an established human-derived cell line that could be used 
to model osteoblast function. 
 
Figure 3.4: Phylogenetic tree of 100 vertebrate species. Human is highlighted in green. The branches that connect 
the species carrying the G>A transition equivalent to the recurrent DCD variant, are highlighted in red. This group 
represents the order Rodentia. No sequence was available for the golden hamster (greyed out). The chinchilla 
(highlighted in yellow) does not have the G>A transition at this position despite being part of the rodents, likely 
indicating a reversion event. The spotted gar (highlighted in blue) has instead a G>T transversion at this position 
and is the only other species in which this nucleotide is not conserved. 
 





Figure 3.5: Alignment of human FLNA with that from nine species of rodent. Human exon 31 and intron 31 
(greyed) with the equivalent sequences from rodent species. The G>A transition equivalent to the recurrent DCD 
variant is boxed in red. Dots (.) represent bases that are identical to the human sequence while dashes (-) indicate 
where there are gaps. Orange boxes indicate the nucleotides that are different to human but same within this group 
of rodents. The blue triangle indicates the location of the -48 cryptic splice site used in DCD. Sequences were 
obtained from Ensembl version 101 (31), and transcript IDs are listed in Appendix B. 
 




3.1.5 Human U2OS cell line can be stimulated to form a mineralised matrix 
In the previous sections, it was established that mice do not normally express the mis-spliced 
isoform of FLNA and therefore MC3T3-E1 should be useful for studying the functional 
consequences of DCD-FLNA. However, it was thought possible that the interspecific 
differences could give rise to other issues that could interfere with future experiments.  Hence, 
a human cell line to model osteoblast function was sought so that it could be used alongside or 
instead of the MC3T3-E1 cell line. 
U2OS is a cell line that was isolated from a human osteosarcoma (143). Osteosarcoma is a 
primary bone cancer that consists of cells originating from mesenchymal stem cells which, at  
some stage of commitment to the osteoblastic lineage, have lost their ability to terminally 
differentiate (144). Cell lines derived from osteosarcoma are therefore commonly used to model 
osteoblasts. However, several studies have claimed that U2OS are unable to form mineralised 
matrix based on the finding that they express little to no functional alkaline phosphatase (ALP) 
under normal culture conditions (145,146). 
I therefore hypothesised that U2OS, if cultured in the appropriate conditions, would undergo 
osteoblastic differentiation to form a mineralised matrix. A mineralisation assay was 
undertaken: U2OS cells were seeded in 24-well plates at a density of 5 x 104 cells/well and 
allowed to adhere for 24 hours. Media was changed to differentiation media containing 
50 μg/mL ascorbic acid, 10 mM β-glycerophosphate, and 0.02 μM dexamethasone – this 
timepoint was taken as day 0. Cells were fixed at days 0, 2, 6, 10, 15 and 20, and then stained 
with Alizarin Red S to visualise the formation of calcium deposits. Figure 3.6 shows the stained 
cells when viewed under bright field microscopy. All images were taken at the same 
magnification, although the cells appear smaller in the later time points due to increased cell 




particularly evident after 20 days, thus demonstrating the ability of U2OS to form mineralised 
matrix. This result confirms the utility of this cell line for investigating the effects of 




Figure 3.6: Alizarin Red S staining for calcium deposits produced by U2OS cells after being cultured in the 
presence of ascorbic acid, β-glycerophosphate, and dexamethasone for 0 days (A), 2 days (B), 6 days (C), 10 days 










3.1.6 AONs could not reproduce the mis-splicing event responsible for DCD 
Mouse-derived MC3T3-E1 and human-derived U2OS were chosen to be used for modelling 
osteoblast behaviour. The next step to investigate the functional consequences of the 
mis-spliced variant of FLNA was to develop a method to introduce the expression of 
DCD-FLNA into these cells. 
Antisense oligonucleotides (AONs) were employed for this purpose. AONs are modified RNA 
or DNA molecules that are designed to hybridise to complementary sequences in target 
pre-mRNA molecules (125). They disrupt normal splicing by interfering with the binding of 
trans-acting splicing factors, either directly by acting as a steric block, or indirectly by altering 
the secondary structure of the pre-mRNA molecule (147,148). The outcome of this is 
commonly whole exon exclusions and thus AONs are also known as splice switching 
oligonucleotides (147). 
A suite of AONs  designed to overlie this 5’ splice region (of human FLNA exon 31 and mouse 
Flna exon 30; see Appendix B for transcript IDs) were evaluated in silico using the guidelines 
described by Aartsma-Rus (125). The 3’ end of an oligonucleotide has been found to be 
important for annealing (149), therefore, two oligos were designed for each of mouse and 
human: the first had the  3’ nucleotide binding to the position of the recurrent variant (final 
nucleotide of the exon), and the second binding to the position of the variant associated with 
the atypical case of DCD discussed in section 1.2.3 (five bases into the following intron) – see 
Figure 3.7. These were designated mAON1 and mAON2 respectively for mouse and hAON1 










Figure 3.7: Positions of AON1 and AON2 relative to the exon-intron junction of interest (human FLNA exon 31, 
mouse Flna exon 30; see Appendix B for transcript IDs). The positions of the recurrent variant (G>A) and the 
variant responsible for the atypical case of DCD (G>C) are marked with red asterisks. -1 indicates the last 
nucleotide of the exon while +5 means five nucleotides into the intron. AON1 (green) and AON2 (purple) are 
lined up to illustrate how their 3’ nucleotides bind to the locations of the recurrent and atypical variants respectively. 
 
MC3T3-E1 cells were transfected with mAON1 and mAON2 to determine whether these AONs 
were capable of reproducing the pathogenic mis-splicing event. It was important that the event 
be exact given that other variants in this region of FLNA produce slightly different skeletal 
phenotypes (discussed in section 1.3.4). Cells were seeded at a density of 1 x 105 cells/well in 
24-well plates and allowed to adhere for 24 hours prior to transfection with AONs at 
1 pmol/well. Cells were harvested 24 hours following transfection for the analysis of RNA 
using RT-PCR. 
RT-PCR showed that both mAON1 and mAON2 induced mis-splicing. This was indicated by 
the presence of an extra band that was absent in our two controls (transfected with an AON 
with a scrambled sequence or untransfected; Figure 3.8A). Sequencing of these PCR products 
was pursued to confirm the identity of these bands. This was achieved by first separating the 
PCR products by cloning into the pGEM-T vector, and then subsequently Sanger sequencing 
directly from plasmid. The first band represented the expected sequence of normally spliced 











form of Flna lacking the final 132 nucleotides (nt) of exon 30 (Figure 3.8B; diagrammatic 
representation of this splicing event in Figure 3.3A #3). This was not the DCD-associated event 
involving the removal of the final 48 nucleotides of exon 30 (analogous to the mis-splicing 
event in humans with DCD). Consequently, it was not deemed appropriate to utilise this 
approach for functional studies.  
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Figure 3.8: AON transfections into MC3T3-E1 were not able to produce the mis-splicing event analogous to that 
observed in DCD. (A) RT-PCR result showing the presence of the wild type Flna transcript in all four samples. In 
samples transfected with mAON1 and mAON2 an additional band indicating a smaller product was observed. (B) 
Sanger sequencing of the RT-PCR products from mAON1 demonstrated that the smaller product was an 
abnormally spliced Flna transcript lacking the final 132 nucleotides (nt) of exon 30. WT, wild type i.e. normally 
spliced Flna; Scramble, sample transfected with AON with random sequence. 
 
Subsequently, AONs were tested on (human) U2OS cells as this approach should avoid any 
issues arising from interspecific differences. Transfections with hAON1 and hAON2 were 
carried out in U2OS cells at 1 pmol/well and harvested after 24 hours as with the MC3T3-E1 
above. RT-PCR was unable to demonstrate the production of any mis-spliced transcripts 
(Figure 3.9A). To exclude the possibility that the dose of the AONs was too low, transfections 




were repeated at concentrations that were two to twenty times the amount of AON i.e. at 2, 5, 







Figure 3.9: AON transfections into U2OS did not reproduce the mis-splicing event observed in DCD, at 
concentrations used for MC3T3-E1 (A), and with higher concentrations (B). WT, wild type i.e. normally spliced 
FLNA; Scramble, sample transfected with AON with random sequence. 
 
The lack of response to transfection with AONs in U2OS cells could have been due to either 
host cell related factors (e.g. cell line specific abnormalities in regulation of splicing) or factors 
relating to the transfection (e.g. transfection reagent efficacy, AON design suitability). The 
former was investigated by testing the AONs in another human cell line. 
Primary human fibroblasts were chosen for this purpose because the initial discovery of the 
mis-splicing event was made in samples of fibromas, which are composed of cells that are 
thought to be fibroblastic or myofibroblastic (12,16). Transfections with hAON1 and hAON2 
were carried out in primary human fibroblasts in the same way as the previous two cell lines. 
RT-PCR on these samples was unable to demonstrate any mis-splicing in transfected fibroblasts 
(Figure 3.10). Having failed to reproduce the desired mis-splicing event in three separate cell 













Figure 3.10: AON transfections into primary control fibroblasts were not able to reproduce the mis-splicing event 
observed in DCD, at concentrations used for MC3T3-E1 (A) and at higher concentrations (B). WT, wild type i.e. 
normally spliced FLNA; Scramble, samples transfected with AON with random sequence. 
 
3.1.7 Construction of a DCD-FLNA plasmid for transfecting into MC3T3-E1  
In the previous section, it was discovered that antisense oligonucleotides were unable to induce 
the DCD mis-splicing event in both mouse and human cell lines. Hence another method to 
introduce the expression of DCD-FLNA into the chosen osteoblastic cell line was needed. Thus, 
an approach involving transient transfections of DCD-FLNA expression plasmids was adopted. 
The MC3T3-E1 cell line would be used for these experiments as they were deemed to be a 
better model of osteoblasts than the U2OS cell line. 
A dual expression plasmid was designed in order to introduce the expression of DCD-FLNA 
alongside short hairpin RNA (shRNA) to knockdown endogenous Flna (Figure 3.11A). 
Ultimately, this plasmid would be transfected into MC3T3-E1 cells and expression levels of 
markers of differentiation would be compared to transfections with the same vector containing 








Figure 3.11: Design of the dual expression plasmid for expressing DCD-FLNA in MC3T3-E1. Human U6 (hU6) 
promoter drives the expression of short hairpin RNA (shRNA). shRNA would have one of: scrambled sequence 
(control; shRNAscr), sequence targeting the 3’ UTR of Flna (shRNA1), or that targeting the 5’UTR (shRNA2). 
The cytomegalovirus promotor (CMV) drives the expression of (A) FLNA (WT or DCD-FLNA) for functional 
assays, or (B) enhanced green fluorescent protein (eGFP) for initial optimisation of transfections. Lengths of the 
sequences are not to scale. 
 
The first step was to test the efficacy of the shRNA-mediated knockdown of endogenous FLNA. 
Two different shRNA sequences were evaluated. The first targeted the 3’ UTR of Flna 
(shRNA1) and the second targeted the 5’ UTR (shRNA2). Constructs with shRNA1 or shRNA2 
under the hU6 promotor were produced as described in methods. Subsequently, the sequence 
encoding enhanced green fluorescent protein (eGFP) was inserted into the second multiple 
cloning site under the cytomegalovirus (CMV) promotor (which drives gene expression in 
mammalian cells; Figure 3.11B). The expression of eGFP would permit the visual detection of 
transfected cells under fluorescence microscopy for the assessment of the transfection 
efficiency. A construct containing an shRNA with scrambled sequence (shRNAscr) and eGFP 
was already available in the laboratory. 
An initial transfection of the shRNA-eGFP plasmids into MC3T3-E1 cells was trialled at 
400 ng/well in 24-well plates. This achieved a suboptimal transfection efficiency of 30-40% as 
determined by fluorescence microscopy. There were no observable differences in the 
transfection efficiency over three time points (24, 48, 72 hours), or between the three plasmid 
constructs (shRNAscr, shRNA1, shRNA2). Cell viability appeared to be adversely affected by 




microscopy). Cells were harvested for RNA after 72 hours to assess the level of knockdown of 
Flna using qPCR. Both shRNA1 and shRNA2 showed some knockdown when Flna mRNA 
levels were compared to cells transfected with shRNAscr (Figure 3.12). 
 
 
Figure 3.12: Knockdown of Flna in MC3T3-E1 by shRNA transfection, measured using qPCR 72 hours after 
transfection. Preliminary result from a single experiment (n = 1) shows that that there was some reduction in 
mRNA levels of Flna with both shRNA1 and shRNA2, and that the knockdown was greater with shRNA1. The 
mRNA levels are expressed as a relative quantity compared to cells that were transfected with shRNAscr. 
 
This preliminary result indicated that both shRNA1 and shRNA2 were capable of silencing 
Flna expression but were limited by the transfection efficiency. Therefore, attempts were made 
to improve the transfection efficiency, and this is detailed below. Meanwhile, insertion of the 
sequences encoding WT- and DCD-FLNA into the vector containing shRNA1 was initiated as 
it had the greater knockdown effect. However, technical difficulties were encountered, and time 
constraints did not allow for this work to be completed. 
Various aspects of the transfection protocol were modified to see if the transfection efficiency 
could be improved. Firstly, the amount of plasmid for transfection was adjusted. Transfections 
with 400 ng, 800 ng, and 1600 ng were trialled. Increasing the amount of plasmid did not 
substantially improve the transfection efficiency. Meanwhile, the cell viability was decreased. 


























The amount of transfection reagent used was also investigated. Increasing the amount of 
Lipofectamine 2000 from 2 μL to 3 μL did not visibly alter either transfection efficiency or cell 
viability. Therefore, I decided to continue using 2 μL of Lipofectamine 2000 per transfection.  
Next, the transfection procedure was modified to improve the cell viability. A modified reverse 
transfection was conducted whereby the MC3T3-E1 cells were seeded at confluency and 
transfection mix added immediately. After five to six hours, the cells were split into four wells 
and allowed to grow. Transfection efficiency (observed after 24, 48, and 72 hours) did not seem 
to be substantially different to that from the initial forward transfection procedure. However, 
there was a significant improvement in cell viability, as determined by cell morphology. 
There was a possibility that the poor transfection efficiency was due to the plasmid preparation 
being of low quality or purity, rather than the cell host being resistant to uptake. To exclude this 
possibility, transfections were trialled in HEK293FT cells which are known to be readily 
transfected. HEK293FT cells were seeded at confluency into 24-well plates and transfection 
mixes with 2 μL Lipofectamine 2000 and 400 ng of shRNA-eGFP plasmid were immediately 
added. Fluorescence microscopy was used to visualise transfected cells 72 hours after 
transfection. Figure 3.13 shows representative images from shRNA1-eGFP transfection into 
MC3T3-E1 and HEK293FT after 72 hours. The cells that have taken up the plasmid fluoresce 
green due to expression of eGFP. Since I observed greater transfection into HEK293FT, the 























   
Figure 3.13: Transfection efficiency in MC3T3-E1 and HEK293FT as observed under fluorescence and bright 
field microscopy, 72 hours after transfection. Cells that have taken up the shRNA1-eGFP plasmid appear green 
under the GFP filter. Bright field (BF) view shows all cells present in the view. ‘Comb’ means combined image 
of GFP and BF. 
 
One further factor that could have been limiting the transfection efficiency in MC3T3-E1 was 
the transfection reagent itself. Three other transfection reagents were trialled (Lipofectamine 
3000, Lipofectamine LTX, FuGENE HD) at several different concentrations as indicated in the 
user manuals. However, none showed any significant improvement in transfection efficiency 
over the original transfection reagent (Lipofectamine 2000). 
None of the above measures were able to produce a satisfactory transfection efficiency, and this 





3.2 Investigating the possible role of CaSR in DCD 
3.2.1 Introduction 
The mis-splicing event responsible for DCD results in the deletion of sixteen amino acid 
residues near the middle of the FLNA protein (16). This region of FLNA has been shown to 
interact with the extracellular calcium-sensing receptor (CaSR) (67,68). This particular 
interaction may therefore be affected by the deletion of these 16 amino acid residues. This 
interaction has been found to be necessary for some of the signaling pathways utilised by CaSR 
(67,68,98,115,116). We hypothesised that the deletion in DCD disrupts osteoblast function by 
inappropriately activating signaling pathways downstream of CaSR – specifically, through the 
CaSR-FLNA-TAK1/TAB2-p38 pathway (see introduction section 1.4.4 and Figure 1.6 for 
details on this predicted pathway). 
Stimulation of CaSR has previously been shown to activate p38 (120). The work in the next 
section aimed to prove the involvement of FLNA and the TAK1/TAB2 complex in this 
signaling pathway. This required the establishment of an assay in which the levels of p38 
activation could be measured following CaSR stimulation. Subsequently FLNA and/or 
TAK1/TAB2 expression would be modulated to determine the necessity of these components 
in this pathway. 
The first step involved the identification of a cell line that expresses CASR. Previous studies 
have used HEK293FT cells that have been stably transfected with CaSR; however, 
endogenously expressed CaSR was preferred as the expression levels were more likely to 
represent physiologically relevant levels. Thus, the next section describes the unexpectedly 




3.2.2 Expression of CaSR in MC3T3-E1 at the mRNA level 
There have been disagreements in the literature about whether the MC3T3-E1 cell line 
expresses Casr (110,112,150,151). It has been proposed that CaSR gene expression may be lost 
during in vitro cell culture (150), and therefore the discrepancies in the literature may represent 
differences between batches of the same cell line. RT-PCR was used to investigate whether the 
MC3T3-E1 used in our laboratory expressed Casr at the mRNA level. 
The PCR conditions for the primer pair used to amplify Casr were optimised using cDNA from 
mouse bone (already available in the laboratory), in which mRNA expression of Casr was 
detected (Figure 3.14). The addition of 20% combined enhancer solution (CES) to the PCR 
reaction and the use of a touchdown program for thermal cycling enabled consistent results to 
be obtained. Sanger sequencing of the PCR product amplified from mouse bone cDNA 
confirmed that the band observed on the gel was indeed Casr. 
RT-PCR on untreated MC3T3-E1 was initially conducted but this yielded no bands. Given that 
this cell line was considered to be pre-osteoblastic, it was hypothesised that expression of Casr 
would be induced during differentiation into mature osteoblasts. To investigate this, RT-PCR 
was conducted on samples obtained from the differentiation experiments described in 
section 3.1.2. No expression of Casr could be detected in MC3T3-E1 over the six days in 
differentiation media (Figure 3.14A). It was then questioned whether six days was long enough 
for the MC3T3-E1 to differentiate sufficiently. Therefore, samples were obtained from 
MC3T3-E1 cells cultured in differentiation media for 10, 15, 20, and 25 days; however, no Casr 











Figure 3.14: Casr expression was not able to be detected in MC3T3-E1 using RT-PCR. cDNA from mouse bone 
was used as a positive control for these experiments. (A) RT-PCR on MC3T3-E1 cultured in differentiation media 
for up to six days did not produce bands for Casr; representative image from three biological repeats. (B) RT-PCR 
on MC3T3-E1 cultured in differentiation media for up to twenty-five days also did not yield any bands. All 
MC3T3-E1 cells used were of less than twelve passages. 
 
3.2.3 Expression of CaSR in human cell lines at the mRNA level 
Following the inability to detect the expression of CaSR at the mRNA level in the MC3T3-E1 
used in our laboratory, a search was initiated to identify a human cell line with such expression. 
Initially, primer sequences obtained from D’Espessailles et al. (152) were tested on cDNA from 
three different cell lines: U2OS, human mesenchymal stem cells that had been cultured in 
osteogenic medium for 25 days (hMSC), and control human fibroblasts (RNA from the latter 
two were already available in the lab and cDNA was synthesized according to section 2.3.3). 
RT-PCR using the standard cycling conditions gave no bands, so a gradient PCR was used to 
determine the optimal annealing temperature. Bands were obtained at annealing temperatures 
between 51.7-58.4C; however, none were of the expected size, and sequencing confirmed that 
the bands observed were the result of off-target amplification. 
A further two primer pairs were designed, but neither yielded any bands apart from primer 




these cell lines rather than there being an issue with all three primer pairs that were tested. In 
order to determine whether there were other cell lines available in the laboratory with CASR 
expression, the Human Protein Atlas (153), available at http://www.proteinatlas.org, was 
consulted. The RT4 cell line derived from transitional cell papilloma originating in the urinary 
bladder was shown to express CASR. While this cell line was not available in the laboratory, 
another cell line from the urinary bladder, T24 (derived from transitional cell carcinoma) was 
chosen to be tested for CASR expression. 
An initial RT-PCR with cDNA from hMSC and T24 using a touchdown program and 20% CES 
produced a single band of a size matching CASR in T24 but not hMSC (Figure 3.15). Sanger 
sequencing of the PCR product confirmed the identity of the band to be CASR. 
 
Figure 3.15: mRNA expression of CASR was detected in T24 cell line but not in human mesenchymal stem cells 
that had been cultured in osteogenic media for 25 days (hMSC Day 25). +RT and -RT indicates the presence and 
absence of reverse transcriptase in the reaction for cDNA synthesis (-RT can serve as a negative control to exclude 
PCR amplification from genomic DNA or contamination from other sources). 
 
However, further repeats of this RT-PCR to confirm the absence of CASR expression in the 
other cell lines initially investigated, revealed that this primer pair was imperfect. Variable 
results were obtained from running the same sample (T24 cDNA) multiple times under the 
same conditions. On several occasions, a single clean band like that in Figure 3.15 was 
observed, while on other occasions, a band of a larger size was present with or without the band 
representing CASR (Figure 3.16). The larger band was confirmed to be off-target amplification 




 RT-PCR on T24 cDNA 
 






   
  
Figure 3.16: Repeats of RT-PCR for CASR on T24 produced different results on three different occasions. All 
were run using the same touchdown PCR programme with 20% CES added. Lane one shows a slightly greater 
intensity for the band representing CASR compared to RPS2, while lane two shows the opposite. Meanwhile, the 
band for CASR is completely absent in lane three. 
 
In an attempt to circumvent the issue of off-target amplification, a further four primer pairs 
were tested using RT-PCR on cDNA from T24 cells. They either gave no bands or gave only 
bands representing non-specific amplification. Subsequently, these four primer pairs were 
tested on plasmid DNA containing sequence from human CaSR cDNA. The purpose of this 
was to allow the examination of the suitability of these primer pairs for PCR amplification of 
CASR without influence from off-target amplification of other cDNA sequences. Three of the 
four primer pairs yielded a single clean band of the appropriate size, indicating that these 
primers can successfully amplify CASR. Following this, various PCR conditions were tested in 
an attempt to achieve specific amplification of CASR. However, the issue was unable to be 
solved. 
None of the primer pairs tested were considered to be sufficiently robust to be able to produce 
conclusive evidence for the absence of CaSR expression. However, given that the positive 
RT-PCR result from T24 was validated using Sanger sequencing, we could conclude with some 
confidence that CaSR expression was present in this cell line. Accordingly, the next line of 
work involving the stimulation of CaSR with calcium and strontium was conducted using the 




3.2.4 Stimulation of T24 cells with calcium and strontium 
The T24 cell line was deemed useful for experiments investigating the hypothesised CaSR-
FLNA-TAK1/TAB2-p38 pathway, given that CASR expression could be demonstrated at the 
mRNA level. 
Previous studies have demonstrated that stimulation of CaSR with calcium or strontium can 
activate ERK1/2 and p38 (154,155). An attempt was made to replicate this result in the T24 
cell line. Cells were seeded at a density of 5 x 104 cells/well in 24-well plates and allowed to 
adhere for 24 hours prior to treatment with calcium or strontium. The cells were treated with 
media containing 10 mM CaCl2 or 10 mM SrCl2, or an equivalent volume of vehicle (H2O) for 
10 minutes. The cells were harvested thereafter and the quantity of phosphorylated p38 (p-p38) 
and phosphorylated ERK1/2 (p-ERK) were measured using western blotting. Both CaCl2 and 
SrCl2 were able to produce a statistically significant, albeit small, increase in p-p38 in T24 cells 
(combined data from three independent repeats). Neither CaCl2 nor SrCl2 were able to produce 














Figure 3.17: Effects of CaCl2 and SrCl2 treatment of T24 on phosphorylated p38 and ERK1/2. T24 were treated 
with media containing 10 mM CaCl2, 10 mM SrCl2, or an equivalent volume of vehicle (H2O) for 10 minutes. 
Representative images of the western blots are shown. The graphs display the combined data from the three 
independent repeats (each with duplicates) as fold change compared to vehicle treatment. Error bars indicate 
standard error of the means. T24 treated with CaCl2, and SrCl2, showed a small but statistically significant increase 
in phosphorylated p38 (A), but no significant change in the levels of phosphorylated ERK1/2 (B). Statistical 
significance was determined using Bonferroni corrected P-values; *P < 0.025; calculated using an unpaired, two 
tailed t-test. 
 
Failing to reproduce the substantial increase in p-p38 or p-ERK observed in previous studies 
involving the stimulation of CaSR (67,68,98,154,155), possible differences in the methodology 
were considered. Several studies had cultured their cells without serum overnight prior to the 
calcium or strontium treatment (67,68,98). This was thought to control the calcium levels in the 
media, as well as the phosphate levels. Phosphate had been shown to act as a non-competitive 
antagonist of CaSR (156) and therefore could have suppressed the response to stimulation with 
calcium and strontium.  Hence, serum-deprivation was pursued. 
The experimental procedure was identical to the above, except that the cells were seeded in 
media without serum supplementation and the treatment media with calcium or strontium was 
also without serum. Figure 3.18 shows the results combined from three independent repeats. 
Neither calcium nor strontium were able to produce a statistically significant change in the 
levels of phosphorylated p38 or ERK1/2 in serum deprived T24 cells. 














































Figure 3.18: Effects of CaCl2 and SrCl2 treatment of serum deprived T24 on phosphorylated p38 and ERK1/2. T24 
were treated with media containing 10 mM CaCl2, 10 mM SrCl2, or an equivalent volume of vehicle (H2O) for 10 
minutes. Representative images of the western blots are shown. The graphs display the combined data from the 
three independent repeats (each with duplicates) as fold change compared to vehicle treatment. Error bars indicate 
standard error of the means. T24 treated with CaCl2, and SrCl2, did not show any statistically significant change 
in phosphorylated p38 (A), or phosphorylated ERK1/2 (B). Statistical significance was determined using 
Bonferroni corrected P-values; *P < 0.025; calculated using an unpaired, two tailed t-test. 
 
While an increase in phosphorylated p38 was observed following treatment of T24 cells (not 
serum deprived) with calcium and strontium, this was very mild in comparison to findings from 
previous studies (154,155). This effect was judged to be too small to be able to show any clear 
effects from modulation of components of this signaling pathway. Hence, the line of work 
investigating the pathway linking CaSR with FLNA was unable to be continued. 
3.3 Summary of findings 
The first approach utilised in vitro models of osteoblasts to investigate the effects of the FLNA 
variant responsible for DCD. I demonstrated that the differentiation of MC3T3-E1 could be 
monitored by measuring the expression levels of Sp7 and Runx2. MC3T3-E1 were derived from 
mice and it was found that the wild type Flna sequence in mice, and other rodent species, 
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(NM_001110556.1:c.5217G>A). This variant causes mis-splicing of FLNA in humans, but no 
such effect was apparent in a publicly available mouse development RNA-seq dataset that I 
investigated. By comparing the nucleotide sequences of Flna in rodents to that from human, I 
was able to identify twelve nucleotide changes that could be preventing mis-splicing of Flna in 
the presence of the human disease variant. A human osteosarcoma cell line, U2OS, was 
investigated for its ability to produce mineralized matrix. It was found that culture in 
differentiation media for twenty days was sufficient for U2OS to produce calcified nodules. 
Subsequently, AONs were used to introduce the mis-splicing event into these two cell lines. 
However, in MC3T3-E1, the mis-splicing of Flna resulted in the removal of 132 nucleotides 
from the end of the exon rather than the expected 48 nucleotides that is removed in DCD. 
Meanwhile, no detectable mis-splicing was observed in human U2OS cells following 
transfections with the AONs. This led to the development of plasmid constructs that were 
designed to knock down endogenous Flna and replace it with DCD-FLNA. Because a 
satisfactory transfection efficiency could not be achieved, no clear results were obtained. 
The second approach aimed to investigate the hypothesis that DCD-FLNA dysregulates the 
signaling pathways downstream of CaSR to induce premature osteoblastic differentiation. 
RT-PCR was used to determine the expression of CaSR at the mRNA level. CASR expression 
was detected in cDNA from mouse bone but not in two osteoblastic cell lines, MC3T3-E1 and 
U2OS. CASR expression was however, detected in T24 (a cell line derived from urinary bladder 
transitional cell carcinoma) and thus this cell line was used for subsequent experiments. 
Calcium and strontium stimulation of T24 led to increased activation of p38, as determined by 









Chapter 4 Discussion 
4.1 Overview 
In the previous chapter, the utility of MC3T3-E1 and U2OS as in vitro model of osteoblasts 
was explored, and this work has highlighted some of the challenges surrounding the study of 
bone diseases. Attempts to reproduce the DCD mis-splicing event and the analysis of the 
nucleotide sequences in this region has uncovered the putative factors that may be influencing 
the splicing of FLNA at this site. Meanwhile, investigations into the possible role of CaSR in 
the pathogenesis of DCD has led to a shift in the hypothesis to include the involvement of cell 
types other than osteoblasts in the development of the skeletal abnormalities in this disease.   
4.2 Developing an in vitro model of DCD 
4.2.1 Modelling of diseases of bone 
In this work, the MC3T3-E1 cell line was chosen as an in vitro model of osteoblasts to study 
the effects of DCD-FLNA. MC3T3-E1 originate from newborn mouse calvaria (130), and are 
commonly used for studying osteoblastic differentiation. Many studies monitor the progress of 
osteoblastic differentiation through the measurement of expression of genes involved in 
differentiation and mineralisation (157–159). 
I conducted a differentiation assay to confirm the utility of three commonly used genes (Sp7, 
Runx2, Col1a1) as markers of osteoblastic differentiation in the MC3T3-E1 cells. A statistically 
significant increase in the expression of the two transcription factors, Sp7 and Runx2, was 
observed from day two in differentiation media. These results are consistent with previous 
reports looking at osteoblastic differentiation in various cells, including MC3T3-E1, 
mesenchymal stem cells (MSCs), and induced pluripotent cells (iPSCs) (159–161). Since the 
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changes in gene expression levels were detectable at a relatively early time point, these markers 
would be useful in investigating how DCD-FLNA might affect the early stages of osteoblastic 
differentiation. 
Interestingly, I was unable to show a significant increase in Col1a1 over the six days of 
MC3T3-E1 differentiation. I did, however, see an increasing trend over this period which could 
simply mean that the duration of treatment was too short, or that the statistical power was 
insufficient for the effect size. 
A recent study by Hwang and Horton (162) has brought into question the validity of MC3T3-E1 
as an osteoblast model. They found that the overall gene expression pattern in differentiating 
MC3T3-E1 was different to that in differentiating primary calvarial osteoblasts (isolated from 
six-week-old female mice) (162). For instance, Sp7 was found to be upregulated in MC3T3-E1 
subclone 4, as confirmed in my experiment, but not in the primary osteoblasts (162). 
MC3T3-E1 are likely to have diverged from the osteoblasts from which they were derived, 
during the processes of spontaneous immortalisation and prolonged in vitro culture. However, 
the observations by Hwang and Horton (162) could have also been influenced by the 
heterogeneous nature of primary cells, which usually have some level of contamination by other 
cell lineages and have a mixture of osteoblasts at various stages of maturation (163). 
Consequently, experiments using primary cells can hold a lot of variability (163), and thus, 
immortalised cell lines are often preferred over primary cells despite the known differences in 
behaviour to normal osteoblasts. 
Among the established immortalised cell lines, MC3T3-E1 are considered to be the best model 
of osteoblasts (164), but the differences between mice and humans generated the need for 
human-derived options to be explored for this project. Cell lines derived from human 
osteosarcoma such as U2OS are commonly used in studies investigating osteoblastic function 
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(164). As briefly described in section 3.1.5, osteosarcoma is a type of bone cancer originating 
from MSCs that have lost the ability to differentiate at some stage following commitment to 
the osteoblast lineage (144). Some reports have questioned the utility of U2OS as an osteoblast 
model (145,146); however, I was able to demonstrate that U2OS can be stimulated to produce 
mineralised matrix following treatment with differentiation media for twenty days – similar to 
another study showing positive staining with Alizarin Red S after four weeks (165). 
This level of mineralisation was, however, quite low compared to other cell lines that have been 
used to model osteoblasts (164), and this suggested that U2OS are slow to produce mineralised 
matrix. There are at least two possible explanations for this. Firstly, U2OS are said to represent 
a very early stage of osteoblast (145) and therefore they may require a long time to differentiate 
before they can begin to lay down the mineralised matrix. Alternatively, U2OS may have 
completely lost the ability to differentiate and instead secrete the mineralised matrix very slowly 
in their original state. One study found that U2OS cultured in differentiation media showed an 
increase in the expression of some but not all osteoblast markers, and suggested that this was 
due to partial and not terminal differentiation (165). U2OS exhibit behaviours different to the 
osteoprogenitors they originated from, probably due to the accumulated genetic and epigenetic 
changes typical of cancers (166,167). But because U2OS still have the capacity to deposit 
mineralised matrix, they would still be useful for investigating the effects of DCD-FLNA on 
mineralisation. However, my interest was in how DCD-FLNA affects normal osteoblastic 
differentiation and therefore U2OS may be less suitable for this experiment. 
The two immortalised cell lines investigated in this work each have their own limitations – 
interspecific differences and cancerous changes. Other osteoblast models that could avoid these 
issues include: primary osteoblasts isolated from human tissues, human mesenchymal stem 
cells (hMSCs), induced pluripotent cells (iPSCs) or transdifferentiation of readily accessible 
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human cells such as dermal fibroblasts (164,168,169). However, these also have limitations 
including poor accessibility, complex differentiation protocols, and/or variability according to 
donor characteristics and the methodology used (163,169,170). The variable nature of these 
options lead to issues around reproducibility, which can complicate the interpretation of results 
compared to when established immortalised cell lines are used. 
Note that only in vitro cultures of osteoblasts have been discussed here. The role of other cells 
residing in bone such as osteoclasts and osteocytes, and the intercommunications between such 
cells is undeniably important (171). Investigating the effect of a genetic variant on bone 
development may therefore be better conducted in co-cultures, or even using animal models. 
However, isolated cultures of osteoblast models still retain value for testing specific hypotheses, 
even with the drawbacks discussed in this section, so long as careful consideration is made in 
the experimental design. It is through such studies that complex intracellular signaling pathways 
can be disentangled and understood. 
4.2.2 Mis-splicing of FLNA in DCD 
Since DCD is caused by a mis-splicing event, the utility of AONs in reproducing this event was 
investigated. AONs transfected into MC3T3-E1 induced a different mis-splicing event to that 
in DCD, presumably due to interspecific differences (discussed in section 4.2.3). Meanwhile, 
the transfection of similarly designed AONs into human U2OS and fibroblast cells did not cause 
any mis-splicing. This latter observation was surprising because it was assumed that this splice 
site was weak, given that two different variants outside the splice donor dinucleotide have been 
shown to cause the mis-splicing event responsible for DCD (16). 
The choice of the target for the AONs is likely to be responsible for the lack of effect observed 
in human cell lines. The AONs were designed to hybridise to the sites of the two DCD variants 
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in FLNA, so that the exact mis-splicing event would preferentially be induced over some other 
mis-splicing event. This did however, mean that the target sites (in human but not mouse) were 
not ideal as it had a high GC content (75%; ideally 40-50%) and contained stretches of six and 
four consecutive guanine bases (the recommendation was to avoid three or more consecutive 
guanines or cytosines) (125). Consequently, strong secondary structures that hinder AON 
binding were likely to be present in the pre-mRNA molecule at this site. One such structure 
could be a G-quadruplex, although the sequence does differ slightly from the canonical 
G-quadruplex sequence (172,173). Note that in the mouse, the intronic sequence does not 
contain these stretches of guanine nucleotides. This may provide an explanation as to why 
similarly designed AONs could readily hybridise to their target and induce mis-splicing when 
transfected into MC3T3-E1 but not in human cells. 
The secondary structure in the human sequence might not only be hindering the binding of 
AONs but also the binding of splice factors. This would impair the assembly of the spliceosome 
at this site. This could explain why this splice site appears to be weak in humans and is 
vulnerable to mutations that further weaken this site to cause mis-splicing in DCD. Further 
exploration of this idea would involve validating the presence of secondary structures using 
experimental approaches such as SHAPE-seq, or immunoprecipitation with selective 
G-quadruplex binding proteins (174,175). 
4.2.3 Regulation of Flna splicing in mice and other rodents 
In the original study that identified the recurrent variant responsible for DCD, there was a brief 
mention that this nucleotide position was not conserved in rodents (16). However, they did not 
specify how the rodent sequence differed from human, and therefore the finding that rodents 
had the equivalent of the recurrent mutation was unexpected. While this variant causes 
mis-splicing in humans (16), I observed no such effect in the mouse developmental RNA-seq 
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dataset from the Wold lab, Caltech (139). This is presumably indicative of differences in the 
regulation of splicing at this site between mice and humans, which prevent mis-splicing in mice. 
Within the few mis-splicing events identified as noise in the RNA-seq dataset, the event 
analogous to that responsible for DCD (utilising the -48 cryptic splice site) was least 
represented. This finding suggests that the -48 cryptic splice site is weaker than the other sites 
in mice (176), which is in contrast to humans, where the -48 site is presumably the strongest 
cryptic splice site as it is this one that is used when the original 5’ splice site is weakened (by 
mutations in DCD). In support of this claim, disrupting the original 5’ splice site in murine 
MC3T3-E1 with AONs, led to the use of the -132 cryptic splice site rather than the -48 site. It 
is possible that this latter observation was an artefact of the mechanism of splice site disruption 
(i.e. altered secondary structure also interferes with the use of the -48 cryptic splice site located 
closer to the original site); however, the -48 splice site being weak in the mouse is a more likely 
explanation given that it is consistent with what was observed in the RNA-seq dataset. 
There may be one or more splicing regulatory factors that differ between humans and 
mice/rodents to account for the two observations mentioned above (i.e. normal splicing in the 
presence of the ‘disease allele’ in rodents, and differences in strength of the cryptic splice sites 
between mouse and human). Earlier, I discussed the possibility that secondary structures in the 
intron was responsible for making this splice site weak in humans but not rodents. However, 
there could also be other factors involved. The regulation of splicing is achieved by the 
combined effects of a wide range of factors which include: DNA methylation, chromatin 
structure, local secondary structure of the pre-mRNA, transcription elongation rate, motifs in 
the sequence for the binding of splice factors, and the expression levels of various proteins and 
RNA involved in splicing (177). Broadly speaking, these factors can be organised into two 
groups (178). The first group is comprised of factors that are related to the nucleotide sequence 
Discussion 
 88 
and are termed cis-acting features. The second group includes factors which bind the nucleotide 
sequence at or near the region of interest – termed trans-acting factors. 
Most interspecific differences in splicing regulation have been found to be cis-directed 
(179,180). Hence, possible cis-acting features that could be responsible for the differences 
between mice and humans, were investigated using a phylogenetic approach. Comparison of 
the nucleotide sequences from nine rodents with that from human revealed that there were 
twelve changes in cis with the G>A transition. This might not be a complete list of the possible 
cis-acting features responsible for the differences between mice and humans in the regulation 
of splicing at this site. Firstly, only the exon and intron involved in this splice site was inspected. 
Although most cis-acting features are located relatively close to the splice site concerned, there 
could also be relevant factors outside this region (181). Secondly, nucleotide changes were 
included only if they were conserved among the rodents. The motifs that provide sequence 
specific binding sites for trans-acting splicing factors are degenerate (182,183), which means 
that changes that differ within rodents may still be important. However, given that the 
nucleotide position of the G>A transition is highly conserved over a wide range of vertebrate 
species, I hypothesised that the cis-acting feature(s) protecting this site from mis-splicing was 
linked with the G>A transition, and therefore be identical within this group of rodents.  
Minigene splicing assays could be used to distinguish the changes that affect splicing from 
those that are simply a result of genetic drift and not of functional effect. This would first 
involve the construction of a plasmid containing the human sequence of several exons and 
introns flanking the splice site of interest. The recurrent DCD variant (G>A at the end of exon 
31) would be inserted into this construct along with one or more of the changes identified in 
Figure 3.5 to see whether any (combination) of these features could rescue the mis-splicing 
event. This work was in fact initiated during the course of the project but technical difficulties 
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in plasmid construction prevented this from being completed. Identification of the precise 
features involved in splice site recognition could help contribute to our understanding of the 
regulation of splicing. This knowledge can be applied to other splice sites to aid the 
interpretation of genetic variants for diagnostic purposes or to help identify targets for 
therapeutic interventions which involve the modulation of splicing. 
4.3 CaSR in the pathogenesis of DCD 
4.3.1 Expression of CaSR at the mRNA level 
This second line of work aimed to explore the hypothesis that the skeletal manifestations of 
DCD arise through the disruption of a proposed pathway that involves FLNA and CaSR (see 
Introduction section 1.4.4 and Figure 1.6). Firstly, the expression of CaSR at the transcript level 
was investigated using RT-PCR. Consistent with previous literature (100,184), expression of 
Casr could be demonstrated in mouse bone using this method, thus supporting the possible role 
of CaSR in bone. 
The expression of Casr, however, could not be detected in the osteoblastic MC3T3-E1 cell line 
using the same method. RT-PCR was repeated on MC3T3-E1 that had been cultured in 
differentiation media for up to twenty-five days, but expression of Casr could not be detected 
in any of the time-points examined. This suggests that Casr is not expressed at any stage of 
differentiation between pre-osteoblast and mature osteoblast. 
However, rather than the complete absence of Casr, it is more likely that this finding reflects 
very low expression levels which RT-PCR lacks the sensitivity to detect. Indeed, the original 
study that demonstrated the expression of Casr in MC3T3-E1, reported difficulties in 
amplifying Casr using ordinary Taq DNA polymerase (110). Using qPCR, Yasukawa et al. 
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(112) showed that the mRNA levels of Casr in MC3T3-E1 was a hundred-thousand times lower 
than that of Gapdh, or a thousand times lower than Runx2. This low level of expression is 
probably responsible for the mixed reports in the literature regarding the expression of CaSR 
in this cell line (110,112,150,151). 
Low expression of CASR also appears to be a feature of human cell lines and is likely 
responsible for the supposed technical difficulties encountered in attempts to amplify CASR 
using RT-PCR. None of the 69 immortalised human cell lines in the Human Protein Atlas 
(http://www.proteinatlas.org) (153) show very high CASR expression levels when compared to 
the data from tissue or single cell RNA-seq present in the same database. 
The finding that CASR/Casr expression could be detected from mouse bone (represents mostly 
osteocytes (171)) but not in two osteoblastic cell lines (MC3T3-E1 and U2OS) might lead to 
the conclusion that CaSR expression is of greater importance in osteocytes than osteoblasts. 
However, it is also possible that the transcript levels of CASR/Casr in MC3T3-E1 and U2OS 
do not accurately reflect that of osteoblasts in vivo. Low expression of CASR/Casr in these cells 
could have been due to the in vitro culture conditions or perhaps is a feature of all immortalised 
cell lines. It would be prudent to investigate this further, either by comparing the expression of 
Casr between osteocytes and osteoblasts in vitro (e.g. murine osteocytic MLO-Y4 cell line vs 
murine osteoblastic MC3T3-E1) or in vivo using single cell RNA-seq. 
The original motive for this line of work was to identify a cell line, preferably exhibiting 
osteoblastic behaviour that could serve as a workhorse for the investigation of the CaSR 
signaling pathway. Hence, my interest was in the expression of CaSR at the protein level rather 
than at the transcript level. While transcript levels are commonly used as a proxy for the protein 
expression, the variability in the RNA-to-protein (RTP) ratios between different genes can 
make this an inaccurate estimate (185). The study by Yasukawa et al. (112) found that, while 
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the expression of Casr in MC3T3-E1 was substantially lower than that of Runx2, the proteins 
level of CaSR was actually greater than that of Runx2. To account for this observation, CaSR 
must have a high RTP ratio. This could be mediated by high translational efficiency and/or high 
protein stability (185). No studies have looked into these factors, although, one study did 
describe CaSR to be a relatively stable with a protein half-life of ~8h (186). Given that the level 
of CaSR in MC3T3-E1 has been demonstrated to be functionally relevant in several different 
studies (112,120,187), it is possible there is functional CaSR in those cell lines that I failed to 
demonstrate expression using RT-PCR. Methods to detect the protein directly such as western 
blotting, immunocytochemistry, or enzyme-linked immunosorbent assays (ELISA), should be 
pursued in the future to investigate this. This has highlighted the importance of using multiple 
detection methods in confirming the expression of a specified protein in tissues or cultured 
cells. 
4.3.2 CaSR-mediated MAPK activation in T24 cells 
Following the identification of the T24 cell line as one that expresses CaSR, experiments to 
investigate CaSR-mediated activation of MAPK signaling was initiated. I was able to 
demonstrate a slight but significant increase in phosphorylated p38 following stimulation with 
calcium and strontium, but no change in phosphorylated ERK1/2 was observed. The effect sizes 
were smaller than what had previously been reported in similar experiments (154,155,188,189). 
There could be several factors that are contributing towards the observed discrepancy. 
Firstly, low levels of CaSR in T24 cells may be producing an accordingly small response to 
calcium stimulation (190). I did not collect data on the levels of CaSR protein in this cell line 
and therefore it is unclear whether this could be responsible (see previous section for discussion 
on the levels of expression of CaSR at the protein and transcript levels). 
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Secondly, technical issues or insufficient optimisation could be at work here given the wide 
range of differences in the methods utilised in previous studies (151,154,155,187–189,191). 
For instance, the concentration of calcium used to stimulate CaSR ranges from 2 mM to 10 mM 
(155,187), and the duration of treatment from 5 minutes up to 2 hours (151,191). The conditions 
required to elicit this transient response appears to vary substantially between cell lines, which 
is expected given that different tissues have their own specific response to a given stimulus. 
The physiological role of CaSR in transitional epithelium, from which the T24 were derived, 
remains unclear (192). Thus, downstream signaling pathways other than p38 or ERK1/2 might 
instead be activated following stimulation of CaSR in T24 cells. 
The cellular context is clearly an important determinant of the intracellular signaling pathways 
that are activated upon stimulation of a given receptor. As discussed in the introduction, the 
relationship between CaSR and FLNA has shown to vary between different cell lines. This 
might account for the apparent absence of calcium and parathyroid hormone abnormalities in 
individuals with DCD despite this being a major feature of disorders arising from pathogenic 
variants in CaSR (7,88). Future work aiming to elucidate the relationship between CaSR and 
FLNA in the cells of bone and comparisons with that in the parathyroid and kidney may be able 
to confirm this hypothesis. 
4.3.3 Reconsideration of the role of CaSR in DCD 
At the outset of this project, I hypothesised that the dysregulation of CaSR signaling occurred 
in osteoblasts to produce the abnormal bone phenotype. However, the finding of Casr 
expression in mouse bone, alongside the apparent absence of expression in two osteoblastic cell 
lines, has introduced the possibility that osteocytes may have a role in the pathogenesis of DCD. 
While the role of CaSR in osteoblasts have been extensively studied, this has not been the case 
for osteocytes and as such, the role of CaSR in this cell type remains elusive. It might therefore 
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be reasonable to propose a hypothesis where DCD-FLNA activates pathways downstream of 
CaSR to cause premature differentiation of osteoblasts into osteocytes. This could be 
investigated in a similar way to the differentiation assay conducted for the MC3T3-E1, but 
instead looking at the expression levels of genes specific to osteocytes. 
Other Mendelian diseases of bone attributed to osteocytic dysfunction, do however have a 
different skeletal phenotype compared to that of DCD. For example, sclerosteosis and van 
Buchem disease exhibit thickening of the skull bones, which is not seen in DCD (193). Until 
recently, the study of osteocytes has largely been neglected because of the difficulties 
associated with isolation and culture of these cells (194). With the rapidly expanding 
understanding of the role of the osteocyte in bone, it is expected that further skeletal phenotypes 
will become associated with osteocyte dysfunction and perhaps the features observed in DCD 
may fit in this phenotype. 
4.4 Clinical applications of findings 
The first part of my project highlighted some of the key challenges faced in studying this 
disease, including the issues associated with modelling skeletal diseases in vitro. I was not able 
to obtain any clear results regarding what effects DCD-FLNA might have on osteoblasts due to 
technical difficulties with the plasmid transfection procedure. Other methods of transfection 
(e.g. electroporation) or gene editing techniques to introduce the disease variant could be 
explored in future work. Nevertheless, there were some discoveries surrounding the factors 
influencing splicing at this site which could lead on to the development of therapeutic 
interventions that target this process. 
With regards to treatment and management of DCD, most of the manifestations are congenital 
and therefore not easily altered; however, the digital fibromata that develop after birth may 
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prove to be a target. Currently, there are no effective treatments for these fibromata. 
Intralesional corticosteroids and cryotherapy have been found to be ineffective (18), and 
surgical resection has been associated with recurrence and damage to the surrounding tissues 
(10). Although these fibromata do eventually regress with time, they can be debilitating while 
they are present and can cause permanent contractures in the most severe cases (10). As such, 
the development of prophylactic or therapeutic interventions that decrease mis-splicing to 
prevent or suppress growth of these lesions would undoubtedly be beneficial for these 
individuals. 
By contrast, introducing this mis-splicing event into individuals not affected by DCD could 
also prove to have a therapeutic application. While more work is needed to understand the exact 
effects of DCD-FLNA on bone cells, it appears that the skeletal manifestations in DCD are 
hyperostotic. Therefore, it may be possible unleash the osteogenic potential of the mis-spliced 
form of FLNA in a controlled manner in settings where this may be beneficial, for example, to 
accelerate fracture healing. 
Meanwhile, the second part of my project, which focused on the possible involvement of CaSR 
in the pathogenesis of DCD, has laid a foundation upon which this hypothesis could be 
investigated further. Exploration of the relationship between CaSR and FLNA may uncover a 
signaling pathway within which targets for therapeutic interventions may lie. Already, CaSR 
has been the target for the development of therapeutic approaches to improve bone anabolism 
(184). Strontium ranelate has been used to treat postmenopausal osteoporosis; however, it is no 
longer indicated for this condition in New Zealand due to the increased cardiovascular risk 
(195). More in depth studies of pathways specific to osteoblasts or osteocytes might allow better 
targets to be identified. 
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4.5 Future perspectives 
The study of DCD is complicated by the X-linked nature of this disease. Readily accessible 
patient cells such as skin fibroblasts and peripheral blood leucocytes rarely ever express the 
disease allele due to the extremely skewed X-inactivation patterns (9,16). Meanwhile, the 
presence of skewing in other tissues is less clear. In the atypical case of DCD introduced in 
section 1.2.3, X-inactivation was highly skewed to favour the expression of the normal allele 
in affected lung tissue but not in the affected heart tissue (which had ~60% expression of disease 
allele). Evidently, the selection against cells expressing the disease allele begins after the 
development of abnormalities in affected organs. When exactly and why the skewing becomes 
established is unclear. It is possible that affected cells have decreased proliferative capacity, 
although, this hypothesis conflicts with the observation of digital fibromata (tumour growth) as 
a manifestation of this disease. Regardless, whether skewing of X-inactivation is present in 
bone tissue is currently unknown, since such tissues have not been studied due to 
inaccessibility. 
Animal models would be useful for the study of this disorder. But note that rats and mice already 
have the equivalent of the recurrent DCD variant, as discussed earlier, and therefore simply 
introducing the nucleotide variant into these models is not possible. Instead, a ‘knock-in’ model, 
which involves replacing the murine Flna locus with the human FLNA sequence containing the 
DCD variant, could be used (196). There are some caveats around using this approach, but the 
validity of this model could be confirmed by analysing the mouse phenotypes and comparing 
them to the phenotypes observed in individuals with DCD. 
Ideally, the study of hemizygous males would allow a clear signal to be obtained, although, 
conditional alleles would need to be used given that this variant is presumably embryonic lethal. 
Alternatively, female mice could be investigated using single cell RNA-seq, a technique that 
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could be used to sort cells based on whether the disease allele is transcriptionally active or not 
(197). This could be used to gain some insight into the transcriptomic effects of DCD-FLNA 
in various cell types. 
Embryonic tissue would be of interest given that this is when the disease is active in causing 
abnormal development of affected organs. While bone cells such as osteoblasts, osteocytes, and 
osteoclasts would be an obvious choice to investigate, it may also be of interest to look at 
embryonic parathyroid, given the proposed hypothesis of CaSR involvement in the 
pathogenesis of DCD. 
Presumably, individuals affected with DCD do not have abnormal serum calcium or PTH levels 
since none of the clinical reports mention these, bar one which stated that routine blood 
examinations were unremarkable (7). However, we cannot rule out the possibility that calcium 
and PTH abnormalities exist prenatally which is when the abnormal skeletal development 
begins. As mentioned in the introduction, the skeletal manifestations of DCD differ somewhat 
from the allelic OPDSD conditions. Prenatal PTH abnormalities could be a mechanism unique 
to DCD, that contributes to the skeletal abnormalities. 
4.6 Conclusions 
The main goal of this work was to investigate the pathomechanisms that underlie the skeletal 
manifestations of DCD. The first part of this work uncovered some of the putative factors 
influencing the mis-splicing of FLNA in DCD. These factors can be explored further to better 
understand how the mis-splicing of FLNA might be manipulated. Meanwhile, investigations 
into the possible involvement of CaSR in this mechanism, revealed the unexpectedly low 
expression of CaSR mRNA in osteoblastic cell lines and the comparatively higher expression 
in osteocytes. The role of CaSR in the osteocyte is currently unclear and is something that 
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should be explored in future work. Steps taken to understand the of the pathogenesis of this rare 
skeletal dysplasia will lead to a greater understanding of bone biology and is hoped that it could 
aid the development of more targeted treatment and management strategies for various 
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Transcripts used for alignment of FLNA sequences 
Species Ensembl transcript ID Exon # 
Human (Homo sapiens) ENST00000369850.10 31 
Squirrel (Ictidomys tridecemlineatus) ENSSTOT00000005104.3 31 
Lesser Egyptian jerboa (Jaculus jaculus) ENSJJAT00000018989.1 30 
Prairie vole (Microtus ochrogaster) ENSMOCT00000010136.1 31 
Chinese hamster (Cricetulus griseus) ENSCGRT00000003103.1 30 
Mouse (Mus musculus) ENSMUST00000033699.12 30 
Rat (Rattus norvegicus) ENSRNOT00000079889.1 29 
Mole rat (Heterocephalus glaber) ENSHGLT00000002405.1 30 
Guinea pig (Cavia porcellus) ENSCPOT00000039584.1 30 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Tris-HCl 0.5 M, pH 6.8 
UltraPure Tris Buffer (Invitrogen)   30.285 g 
HCl (ACS reagent, 37%; Sigma)   Add until pH is 6.8 
Distilled H2O      Make up to 500 mL 
Tris-HCl 1.5 M, pH 8.8 
UltraPure Tris Buffer (Invitrogen)   90.855 g 
HCl (ACS reagent, 37%; Sigma)   Add until pH is 8.8 
Distilled H2O      Make up to 500 mL 
6X denaturing-SDS loading dye for western blot 
Tris-HCl 0.5 M, pH 6.8 (see below)   3 mL 
Glycerol 50% (Sigma)    2 mL 
SDS 20% (Sigma)     4 mL 
Bromophenol blue (BDH)    0.01 % w/v 
Distilled H2O      1 mL 






10% polyacrylamide gel with 0.1% SDS for western blot 
Tris-HCl 1.5 M, pH 8.8    1500 μL 
40% Acrylamide/Bis solution, 19:1 (Bio-Rad) 1500 μL 
SDS 20% (Sigma)     30 μL 
Ammonium Persulfate, 1% w/v (Sigma)  60 μL 
TEMED (Sigma)     5 μL 
Distilled H2O      2905 μL 
Tris/Glycine running buffer with 0.1% SDS 
UltraPure Tris Buffer (Invitrogen)   2.42 g 
Glycine (Sigma)     11.53 g 
SDS 20% (Sigma)     4 mL 
Distilled H2O      Make up to 800 mL 
Tris/Glycine transfer buffer with 10% isopropanol 
UltraPure Tris Buffer (Invitrogen)   0.303 g 
Glycine (Sigma)     1.44 g 
2-Propanol (Merck)     10mL 
Distilled H2O      Make up to 100 mL 
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